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ABSTRACT
The treatment of tumours using microbeads for embolization and drug delivery is a
widely used, but often ineffective, technique. In this work, we aim to produce
microbeads for this application with four main improvements: visibility, targetability,
degradability, and an alternative route for drug loading. We accomplish this through the
fabrication of ~100µm diameter microbeads composed of poly(vinyl alcohol) (PVA),
iron oxide nanoparticles, and cellulose nanocrystals (CNC) using a custom-designed
microchannel system. Characterization demonstrated that microbeads were magnetic,
as well as visible under clinical CT. Separately, the dissolution of PVA iron oxide
hydrogels exposed to different environmental conditions was studied. Iron release and
mass loss was demonstrated, and the weakening of material was confirmed using
mechanical testing. This shows the potential for microbeads composed of this material
to ‘degrade’ over time. PVA iron oxide CNC microbeads are promising as a
multifunctional visualization and delivery system.

Keywords
Multifunctional delivery system, microbeads, trans-arterial chemoembolization,
localized delivery, computed tomography, microfluidics, poly(vinyl alcohol), iron
oxide nanoparticles, cellulose nanocrystals, degradable hydrogel
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CHAPTER 1 – Overview and Objectives

1.1 Overview
The development of multifunctional drug delivery systems addresses many of the
issues associated with current approaches to cancer treatment, such as the toxic and
unspecific nature of chemotherapy. Microbeads are widely used as a drug-eluting
embolization material in the treatment of hepatocellular carcinoma. However, there are
specific areas of improvement that are needed. Namely, microbeads that can be
visualized with the use of clinical imaging techniques, degraded following therapeutic
use, and be better targeted to a specific location are extremely desirable. They must also
have the ability to load and release drug molecules in a favourable way.
To achieve these goals, we investigate the production and use of a multifunctional
system composed of a poly(vinyl alcohol) (PVA) matrix loaded with iron oxide
nanoparticles and cellulose nanocystals (CNC). The iron oxide nanoparticles, which are
biocompatible, non-toxic, and have magnetic properties, act as a contrast enhancement
agent that allows visualization as well as magnetic targeting. Additionally, the
incorporation of iron oxide changes the properties of a PVA hydrogel to allow for
subsequent dissolution of the material. CNC, which are also biocompatible, can provide
a high surface area for drug loading within the microbeads.
The first section of this thesis describes the design of a system for production of these
microbeads, as well as bead fabrication. Microbeads are characterized in terms of size,
structure and morphology, iron oxide presence in the form of magnetite, and iron oxide
nanoparticle distribution. They are also imaged under computed tomography (CT) to
demonstrate their visibility.
The second part of this work relates to the dissolution of this material. PVA is a
biocompatible and biostable polymer that can be physically crosslinked, using a low
temperature thermal cycling process (LTTC), to form nondegradable hydrogels, useful
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in many biomedical applications. In addition to physical crosslinking, iron oxide
nanoparticles have been shown to provide a certain level of crosslinking in PVA. We
investigate the use of iron oxide as a crosslinking agent in conjugation with the LTTC
process to form a dissolvable PVA hydrogel.
The focus of this work involves the production of multifunctional microbeads with
many advantageous properties that make them a desirable candidate for use in cancer
treatment. Through the production and investigation of PVA iron oxide CNC
microbeads, we will demonstrate their unique and multifunctional properties, and the
study of the PVA iron oxide hydrogel will explore the dissolution properties of this
advantageous biomaterial.

1.2 Objectives
1. To develop a method of production for PVA iron oxide CNC microbeads of an
appropriate size and successfully demonstrate their fabrication.
2. To characterize the microbeads and examine them under clinical imaging
techniques to demonstrate visualization.
3. To study the use of iron oxide incorporation as well as the LTTC process to
crosslink PVA hydrogels and study their dissolution as a function of changing
environmental conditions.
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CHAPTER 2 – Literature Review

2.1 Cancer and Hepatocellular Carcinoma
Worldwide each year, there are an estimated 12.7 million new cases of cancer and 7.6
million cancer deaths [1]. Even though there are numerous treatment options, more than
50 percent of patients eventually die from progressive metastasis because they either do
not respond to therapy or they relapse afterward [2].
Specifically, primary liver cancer is the fifth most commonly diagnosed type of cancer
in men and the seventh most common in women worldwide. In terms of deaths caused
by cancer, liver cancer ranks second in men and sixth in women. In 2008, an estimated
748,300 new liver cancer cases were diagnosed worldwide. Hepatocellular carcinoma
(HCC), a primary malignancy of the liver, makes up 70% to 85% of total global liver
cancers [3]. The main contributors of HCC are the hepatitis B virus infection, hepatitis
C virus infection, alcohol-related cirrhosis and possibly nonalcoholic fatty liver disease.
In many parts of the world, incidence rates of liver cancer are increasing. In some
developed regions, this could possibly be a result of the obesity epidemic and rise in
hepatitis C virus infection [4-6].

2.2 Current Treatment Methods and Products
Treatment of HCC can be either curative or palliative. Curative treatment, which results
in complete responses in a large percentage of patients, includes resection, liver
transplantation, and percutaneous treatments such as ethanol injection, cryoablation or
radiofrequency ablation. However, less than one third of patients, are eligible for these
treatments [7] based on factors including the stage of the underlying disease, the cancer
progression and the liver functional status [2,8]. The next options, for intermediate
HCC, include chemotherapy, embolization, or a combination of the two –
chemoembolization. The best candidates for chemoembolization are patients with
preserved liver function and asymptomatic multinodular tumours that have not spread
into vessels or outside of the liver [7,8].
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Trans-arterial chemoembolization (TACE) is a technique that has been used clinically
for over 30 years [9] as a loco-regional treatment, which is essentially the physical
targeting of therapeutics to a particular site (eg. drug infusion into the organ bearing the
tumour). TACE (Figure 2.1) is a minimally invasive procedure, performed by
interventional radiologists, in which chemotherapy, followed by an embolization agent,
is infused as close to the tumour site as possible, through a catheter. This is done by
feeding a catheter through the femoral artery, into the hepatic artery and then to specific
branches in attempt to limit delivery to tumour tissue. Gelfoam in 1mm cube
preparations is a commonly used embolization agent, but poly(vinyl alcohol), alcohol,
starch microspheres, metallic coils, or autologous blood clots have also been used
[8,10-14]. Typically, Lipiodol®, an oily, radio-opaque contrast agent, is injected along
with the chemotherapeutic agent [8].

	
  

Figure 2.1 Schematic describing the principles of TACE. Access is gained in the
femoral artery (left) and a hepatic artery is selected by use of a guidewire and a
catheter (middle). A micro-catheter is then often positioned in a tumour feeding
artery (right). From this location, TACE is performed by infusing a mixture of
chemotherapeutics and embolic agents (right). Reprinted from [15] with
permission. Copyright (2012) Elsevier
Because HCC is a primary liver cancer, TACE therapy is an appropriate treatment
approach. Alternatively, metastatic liver cancer can occur, which results from
metastasis of a primary tumour in another location in the body. Due to the differences
in the vasculature of these two types, and the need for a more systemic treatment
approach for metastatic cancers, treatment with TACE is typically used for primary
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cancers [2]. Blood supply to the liver is provided by the hepatic artery (25%) and the
portal vein (75%). Most liver tumours receive blood principally from the hepatic artery
[2]. Therefore, for intermediate HCC tumours, prevention or limitation of blood flow
through the hepatic artery to the tumour is a logical means of causing ischemia, which
leads to tumour necrosis.
Chemotherapy is known to have very harmful side effects for patients due to the high
toxicity of the drugs administered. Systemic delivery of these therapeutic agents results
in the unwanted killing of non-cancerous tissue. Furthermore, rapid clearance of the
drug molecules is an issue, and to overcome this, multiple doses of these toxic agents
are required in order for the desired effect to take place on the tumour. Even locoregional treatment, where the drug is infused directly into the organ containing the
tumour, does not solve these problems. Controlled delivery devices offer a solution.
Liposomes, hydrogels, polymer-based disks, rods, pellets and micro or nanoparticles
are all systems that are used to encapsulate therapeutic agents and provide sustained
release [16]. Drug-encapsulating polymer microspheres is one category of drug delivery
system that has been studied extensively to release therapeutic agents in a controlled
rate over a longer period of time compared to conventional approaches. Moreover, the
ability to tune loading and release rates allows for better control and tailoring to a
specific application. Additionally, drugs that are otherwise rapidly cleared by the body
can be administered in fewer doses. The benefits provided by controlled delivery
devices often result in an increase in patient comfort and compliance [16]. Polymer
microspheres are a good option because they can be biocompatible, provide high
bioavailability, and sustain release over a long period of time. However, disadvantages
for polymeric microspheres include the difficulty of large-scale manufacturing,
maintaining the stability of drug molecules, and difficulty in controlling the rates of
drug release [16].
More specifically, hydrogels are a subcategory of polymers that possess properties that
are highly advantageous for drug delivery purposes. Hydrogels are crosslinked polymer
networks with high water content. They are highly porous, which allows drugs to
diffuse into the structure during loading, and out during release. Furthermore, hydrogel
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porosity can be controlled by altering the density of crosslinks in the matrix [17].
Finally, they are typically biocompatible due to their high water content and similarity
of their chemical composition and mechanical properties to that of native extracellular
matrix [17]. Advancements have been made toward the development of stimuliresponsive or “smart” hydrogels, which incorporate a triggering mechanism for drug
release such as pH, temperature, pressure, electric field, chemicals, or ionic strength
[18].
Doxorubicin (Dox) is one of the most common drugs used to treat cancer [19]. It is a
useful therapeutic for HCC treatment and its cytotoxicity is a result of several
mechanisms including intercalation in DNA leading to inhibition of DNA replication or
RNA transcription, DNA damage or lipid peroxidation, disruption of DNA unwinding,
strand separation or helicase activity, and topoisomerase II inhibition leading to
apoptosis. Its high toxicity has actually hindered its effectiveness as a treatment option
[20]. Negative effects of Dox include cardiotoxicity, nephrotoxicity, myelosuppresion,
multiple drug resistance, nausea, vomiting, stomatitis, alopecia, vesicant reaction,
radiation recall, and transient memory loss [20]. Many strategies have been explored to
encapsulate Dox in a carrier. Some strategies include encapsulation of Dox within
liposomes

[19,21],

polymeric

micelles

[22-24]

and

nanoparticles

[25,26].

Commercialized products include Doxil®, a PEGylated (stealth) Dox liposome;
Myocet®, a non-PEGylated liposomal Dox formulation; and the DC Bead®.
The DC Bead, the first commercially available embolic drug-eluting bead (DEB), was
launched in 2004 in Europe by a company called Biocompatibles. The beads are made
of poly(vinyl alcohol), modified with N-acryloyl-amino-acetaldehyde dimethylacetal
and crosslinked with 2-acrylamido-2-methylpropanesulphonate sodium (AMPS) salt
forming a spherical bead [2,27]. They are fabricated using an inverse suspension
polymerization technique to produce beads in the range of 100 to 900µm in diameter
[28], and are composed of ~95% water within the network of polymer chains. The
sulphonic acid groups present on the AMPS chains allow for conjugation of drug
molecules through ion exchange. In order for this to occur, the beads are suspended in
solution containing the desired drug molecule. The DC bead is free of drug when given
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to the physician, and is subsequently submerged in a solution containing the drug, like
doxorubicin hydrochloride, for several hours. The positively charged Dox in solution is
able to diffuse into the polymer network and displaces sodium ions bonded to the SO3groups, with a drug uptake over 99% providing there are no additional ions competing
for ion exchange. The maximum doxorubicin loading is 37.5mg/mL of beads. The
doxorubicin drug-eluting bead is called DEBDOXTM, with an alternative being
DEBIRITM, containing Irinotecan, another anticaner drug [2].
DEBs have been shown to be effective in accomplishing tumour necrosis while
reducing systemic chemotherapeutic levels. The release of doxorubicin from DEBs in
DEB-TACE therapy compared to conventional TACE shows a dramatic decrease in the
initial serum doxorubicin levels (Figure 2.2). This suggests that the amount of
chemotherapeutic could be increased to tumour tissue while also reducing toxicity
compared to conventional TACE [29].

	
  

Figure 2.2 Dox serum levels of DEB-TACE and conventional TACE.
Measurements of serum doxorubicin levels at different time points in DEB-TACE
patients (A), and in the conventional TACE group (B). Reprinted from [29] with
permission. Copyright (2007) Elsevier
DEBs are typically used in volumes of 1-4mL to provide therapeutic levels of drug to
the site [2]. Recommendations for the use of DEBDOX include a loading dose of 25mg
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Dox/mL beads usually with a locally administered dose of 100mg Dox (lower than
recommended maximum of 150mg Dox for a given procedure) [27]. Other
recommendations suggest that a total loading of 50-75mg doxorubicin in 2mL (2537.5mg Dox/mL beads) is optimal [30]. A review of recent clinical results concluded
that the optimal available bead size is the 100-300µm range as this size results in less
complete stasis, which allows for repeat treatment, providing the potential for a greater
cumulative dose. This small bead size resulted in fewer and less severe adverse event
rates [31]. Dreher et al. found that even smaller DEBs (70-150µm versus 100-300µm)
were able to penetrate further into the target tissue and had greater spatial frequency or
density [32]. Lee et al. also found that the smaller diameter beads in their study (100300µm versus 300-500µm) were able to reach the tumour, or get in close proximity to
it, more effectively [33]. However, there is a limit to how small the beads can be.
Particles greater than 10µm must be used as small capillary diameter is around 5-8µm
[34]. Furthermore, work completed on embolization in rat models reported that
particles of at least 40µm are required for embolization to prevent distribution to other
organs such as the spleen or lung [35].

2.3 Necessary improvements to current approaches
As was described in a review by Kerr [36], the ideal drug delivery and embolic system
for regional treatment of cancer should be deliverable by catheter, appropriate size for
embolization of target vessels, biocompatible and non-immunogenic, have no drugdevice incompatibility issues, carry a therapeutic dose of a drug, and provide
controlled, local release in therapeutic levels [2]. These goals have been reasonably
achieved with the currently administered DEBs. However, there are still many ways
that this therapy can be improved.
A recent review by Lewis and Dreher discussed loco-regional drug delivery using
image-guided intra-arterial drug-eluting beads. They presented some drawbacks to the
currently available procedures and products and suggested the future directions for
DEB-TACE. Some of these presented suggestions include the need for imageable
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DEB-TACE, the tailoring of bead size to the arterial anatomy of the tumour, the
development of degradable DEBs, and the use of DEB combination therapy [15].
Multifunctional systems, in which two or more materials are incorporated into one
system, have certainly been noted as a beneficial system for cancer therapy because of
the ability to accomplish multiple goals at once. Multifunctional materials are
composite materials that either perform multiple structural functions, or combine nonstructural and structural functions [37]. Polymer coated magnetic nanoparticles
containing fluorescent molecules, tumour-targeting moieties, and chemotherapeutic
agents have been developed and are able to target specific sites, provide imaging
contrast enhancement, and treat the tumour simultaneously [38]. By adding additional
material components that possess unique properties, it could be possible to enhance the
functionality of DEBs. In the following paragraphs, we introduce some aspects that
would be beneficial as added components for drug-eluting beads used for TACE
therapy.
2.3.1

Visibility/ detectability

The current method of tracking the location of drug-eluting beads for TACE therapy
involves infusing a soluble iodinated non-ionic contrast agent, such as the commonly
used CT contrast agent Lipodiol made from iodinated poppy seed oil, with the drugeluting embolization beads. This is done either by injecting beads followed by contrast
agent [39], or mixing the contrast media with the microbead suspension and injecting
them at once [40]. Unless another specific endpoint is desired, once reflux is detected,
that is used as the endpoint for bead infusion [30]. The issues with this are that contrast
media is rapidly cleared by the body [41], meaning that long-term detection of the
beads is not possible. Also, loosely mixed contrast media does not necessarily
demonstrate the presence or location of microbeads [42], and additionally, once the
blood flow is limited due to embolization, it may be difficult for more contrast agent to
reach the site. This lack of intraprocedural imaging feedback has been identified as a
disadvantage of DEB-TACE compared to Lipiodol-based TACE [15,32]. A drugeluting bead with inherent radiopaque or magnetic properties would be beneficial in
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that it would have the ability to be imaged using clinical imaging techniques. This
could be accomplished during the procedure, providing real-time intra-procedural
feedback, as well as providing useful information in follow-up imaging.
A new class of embolic microspheres that are detectable through imaging has been
recently introduced. It has been noted that the ability to image the distribution of DEBs
in tissue in real-time would be useful for choosing particle size to further improve
embolization procedures [33], to help adjust the procedure to specific patients, or to
provide information for combination therapy such as the optimal position for ablation
needles based on areas less concentrated with drug or beads [32]. Additionally, imaging
the final location of DEBs would provide some information in terms of drug
quantification and localization [32] of the dynamic drug levels in a tumour following
DEB-TACE [43]. Namur et al. found that drug distribution after DEB-TACE was
greatest around the beads and existed at 600µm away from the bead edge [44].
Detectable embolic particles that have recently been studied include modified
commercial products such as Embozene® Microspheres with barium sulfate and iron
oxide precipitated into the hydrogel for radiography, CT and magnetic resonance
imaging (MRI) in porcine kidneys [45]; iron oxide-containing Embosphere®
Microspheres made of tris-acryl gelatin for use with MRI [33]; Contour® Emboli PVA
particles modified with gadolinium chelates to the surface for MR imaging [46]; and
the LC Bead® (similar to the DC bead but without loaded drug) loaded with Lipiodol
visualized with fluoroscopy and CT [40]. Additionally, chitosan microspheres
embedded with superparamagnetic iron oxide have been developed for MRI traceable
embolization [47,48].
Lee et al. imaged the distribution of iron-oxide containing tris-acryl gelatin
microspheres after using MR imaging following injection into rabbit liver. Results
displayed a difference in distribution and location of small embolization microspheres
compared to larger ones, with the larger ones being undesirably located outside the
tumour area. This suggests that detectable embolic microspheres could provide useful
information that would help improve TACE therapy technique [33]. Sharma et al.
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demonstrated that Lipiodol loaded LC beads could be detected in vivo in swine liver
and kidney tissue with CT. The visibility was based on the iodine content of the
Lipiodol-loaded microspheres, the distribution volume after embolization, and the
imaging method and post-processing image analysis sensitivities. They showed that
individual beads could be resolved using micro-CT but not clinical CT, and suggested
that if at least 2-3 beads were packed in an artery, optimal visibility with clinical CT
could be achieved. Approximately 0.2-0.25mL of beads could be detected with CT and
approximately 0.4-0.5mL could be detected with fluoroscopy in the final arterial
destination after embolization of the liver and kidney [40].
Following this work, Dreher et al. studied the doxorubicin levels around radiopaque
DEBs. The LC/DC Beads, made radiopaque by the addition of Lipiodol into the bead,
were also loaded with Dox and the beads were delivered to normal swine liver and
kidney and were imaged in vivo with fluoroscopy and CT. It was observed that smaller
beads (70-150µm compared to 100-300µm in diameter) penetrated the tissue more
distally, with a more homogeneous distribution, and roughly 2-fold greater drug
coverage. They also found that transcatheter computed tomography angiography (CTA)
with liquid iodinated contrast shows different results than the eventual bead location
using radiopaque beads, demonstrating that using transcatheter CTA with liquid
contrast is not accurate in approximating the eventual bead location, and radiopaque
beads would better determine this [32].
The development of multimodal embolization particles has also been recognized as a
desirable goal because it would allow procedural imaging to be achieved using multiple
clinical imaging techniques. Embolization particles of 40 to 200µm consisting of a long
polymer with an iodine-containing core and an iron oxide coating were shown to be
visible under fluoroscopy, CT, and MRI [42]. It is suggested that the combination of
multiple modalities could provide the quantifiability of CT along with the sensitivity of
MRI [49], and could be useful for not only intraprocedural imaging, but also follow-up
examinations [42].

	
  

	
  
	
  

12

It is recommended that follow-up CT or MRI be completed two to four weeks
following treatment with DEBs to monitor tumour response. If residual tumour is
detected, further treatment is recommended and typically occurs four to eight weeks
after the original treatment [30]. This indicates that detection of visible DEBs would be
easy to incorporate into current practice and could provide beneficial information as to
the amount and location of existing DEBs.
2.3.2

Degradability

The fate of many DEBs following therapy is currently unknown. When the loaded
chemotherapeutic has been delivered, and treatment is not finished or the tumour
recurs, further DEB-TACE is often needed. According to Lewis and Dreher, “the
current materials are considered non-biodegradable which led to early objections to
DEB therapy since it may not be possible to re-enter the feeding artery once this artery
had been occluded” [15]. Multiple treatments are often needed [31] and a review of
studies of HCC transarterial therapy found that the average number of sessions per
patient was 2.5 ± 1.5 occurring 2 months apart [9]. It has been thought that nonbiodegradable microparticles for TACE therapy should be used for single therapies and
biodegradable versions should be used when repeated therapy is needed so ensure that
the artery is not blocked [35]. In spite of this, non-biodegradable DEBs have been used
clinically and multiple repeat DEB-TACE procedures in the same patient has been
shown possible [50]. This does not, however, mean that there are no issues with the
accumulation of DEBs at the tumour site without the ability to degrade, but that there is
currently no option that properly addresses this. “There is an undercurrent of opinion
that DEB evolution will eventually move in this biodegradable direction as an essential
feature” [15].
Degradability of the carrier is an important aspect to consider for drug delivery.
Polymeric microspheres composed of biodegradable material are one of the most
commonly used drug delivery systems [16]. In terms of microspheres for drug delivery,
the degradability is not only important because it limits accumulation and potentially
toxic side effects, but it also alters the release of the drug molecules incorporated or
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encapsulated within the microsphere. Release from a degradable polymer can follow
any of the following mechanisms: release from the surface of the microsphere; release
through the pores of the microsphere; diffusion through the polymer barrier; diffusion
through a water swollen barrier; and release due to polymer erosion and bulk
degradation [51]. The two main categories of polymer degradation are surface erosion
and bulk erosion [52,53]. Drug carrier erosion may be beneficial because it may allow
for release of drug molecules entrapped in the polymer matrix, resulting in additional or
prolonged release, and also opens up the potential for delivery of more challenging
drug molecules; this includes water-insoluble drugs, which cannot otherwise diffuse
from a DEB, or molecules of high molecular weight [35].
Biodegradable polymers can be natural or synthetic, and break down either
enzymatically or non-enzymatically into biocompatible, non-toxic byproducts [51].
Non-enzymatic degradation or dissolution can occur hydrolytically, or through change
in environmental factors such as pH, temperature, or electric field [17]. Synthetic
biodegradable

polymers

include

polyorthoesters,

polyanhydrides,

polyamides,

polyesters, polyphosphazenes, and natural polymers used for biodegradable drug
delivery include proteins such as albumin, gelatin, and collagen, or polysaccharides
such as starch, cellulose, and chitosan [51].
Poly(vinyl alcohol) is known to be non-biodegradable. (This will be discussed further
in section 2.5.1). In a review on agents and drugs used for TACE therapy of HCC,
Giunchedi et al. described the PVA microspheres, and specifically the DC bead, as
belonging to the non-biodegradable category [35]. In terms of the DC bead, it has been
reported that small beads may be favourable due to less complete stasis, allowing for
repeat treatment [31]. Additionally, obstruction of tumour arteries could prevent
contrast agent perfusion into the tumour, which may inhibit follow-up imaging to detect
viable tumour [29]. It is reasonable to conclude that degradable DEBs would be
beneficial because they would allow more effective repeat treatment and also better
monitoring of tumour progression.
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2.3.3

Targetability

Targeting of drug carriers has been identified as an important area of cancer therapy
and localizing therapeutic agents to a specific area remains a constant challenge of
chemotherapy. Because most chemotherapeutic agents affect any rapidly dividing cell,
the unspecific nature can cause significant harm to surrounding tissue. In the case of
intravenous administration, the drug circulates throughout the body. By directing drug
carriers to a target organ, delivery has the potential to better treat the tumour tissue
through the release of the full drug load to the specific site, as well as limiting toxicity
to other organs or surrounding tissue. Targeting can either be active or passive. In terms
of microsphere encapsulation of drug molecules, active targeting involves molecular
interactions between microsphere surface groups and specific receptors on the cells of
the target tissue. Alternatively, passive targeting occurs based on physical or chemical
properties of the microsphere, for example size or charge [16]. Loco-regional treatment,
as mentioned previously, is accomplished with DEBs by the physical localizing of drug
carriers in close proximity to the target tumour tissue, and size dependent microbead
accumulation in the vessels of the tumour. This is a form of passive targeting that relies
on blood flow to carry microbeads to a general location.
An alternative method of passive targeting is magnetic targeting. Magnetic targeting of
magnetically responsive particles carrying anticancer agents is a method of selectively
localizing drug molecules. This approach has been studied since the 1970s with recent
development of drug loaded ferrogels [54] and magnetic nanoparticles conjugated with
drug molecules [55-57]. Substantial advancements have been made in this area because
of the potential to focus drug carriers to very specific locations. This could be achieved
by dynamically manipulating magnets to focus the magnetic drug carriers [58].
It has been suggested that magnetic carriers could be used to improve TACE therapy
[35]. Pouponneau et al. described the need for better targeting of TACE therapy
particles and four main problems associated with the lack of it: some drug reaches
systemic circulation causing undesirable cytotoxicity; the drug can attack healthy cells;
a painful procedure is experienced due to embolization of healthy blood vessels; and

	
  

	
  
	
  

15

damage to the hepatic artery occurs, limiting the ability to effectively perform
additional treatments. The authors fabricated magnetic iron-cobalt nanoparticles
encapsulated into poly(D,L-lactic-co-glycolic acid) (PLGA) microparticles that could be
magnetically steered by an MRI system [59]. An additional method of targeting or
localizing the DEBs used in TACE therapy could be beneficial in accumulating the
microbeads at a more specific region within the liver.
2.3.4

Improved drug loading and release

It has been suggested that DEBs can pose a problem when there is incomplete killing of
tumour tissue in combination with hypoxic conditions. This could cause cancerous cells
to transform into a more malignant phenotype [15]. Work demonstrating that
embolization-induced hypoxia actually leads to the expression of vascular endothelial
growth factor and angiogenesis [60] supports the idea that additional therapeutics that
block angiogenic pathways could be administered along with current therapeutics for
DEB-TACE [15]. Combination therapy with other anti-cancer agents is also being
studied and the ability to load multiple drugs into DEBs may prove beneficial [15].
Moreover, through the ion exchange drug conjugation currently used in some DEBs, a
limit of drug loading exists. If the loading of the drug molecules into the microbeads
can be enhanced, and the mechanism of drug release altered and tuned, the release can
be sustained over a longer period of time. This would be beneficial in providing longer
treatment without an increase in toxicity or the need for multiple doses of drug loaded
embolic agents. Additionally, there are constraints on the types of drugs that can be
loaded into the current DEBs that load and release drug based on ion exchange. Chief
among these constraints is that the drug molecule must be ionizable [35].
A material that has the ability to increase drug loading and also enable the loading of
multiple therapeutics could prove to be very advantageous for this type of system. In
section 2.5.2.2, the use of cellulose nanocrystals, as an alternative approach to drug
loading that is able to fulfill these requirements is described. Additionally, the control
of drug release kinetics could be accomplished by means of a tunable polymer matrix.
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This is described in section 2.5.1 with the use of a physical crosslinking method for a
poly(vinyl alcohol) drug encapsulation matrix with variable diffusion properties.

2.4 Design Criteria
Based on recent developments in the field of drug delivery, we suggest the addition of
the following criteria to the list of ideal characteristics of a drug carrying embolization
material:
1.

Visible/detectable with the use of clinical imaging techniques

2.

Degradable following therapeutic treatment

3.

Targetable (ie. with application of an external magnetic field)

4.

Alternative drug loading and release mechanism

Other aspects that are considered important criteria for the design of new drug-eluting
beads include the biocompatibility of all materials and the ability to achieve an ideal
microbead size. In the next sections, the materials selected as matrix and the nanoelements to be incorporated will be discussed.

2.5 Materials
2.5.1

Poly(vinyl alcohol) as delivery matrix

Poly(vinyl alcohol) is a polymer that can be transformed into a hydrogel with unique
properties that make it a desirable candidate for use in many biomedical applications.
Hydrogels are three-dimensional networks of polymer chains that maintain a high water
content. PVA is synthesized through the production of polyvinyl acetate via free radical
polymerization, followed by a hydrolysis reaction [61]. This produces a carbon chain
containing secondary alcohol groups, which allow for significant hydrogen bonding in
the presence of water, forming a hydrogel with high water content. In order to stabilize
the hydrogel, several crosslinking techniques are used. The use of chemical
crosslinking agents is quite common. Examples of these agents are formaldehyde and
gluteraldehyde [61,62]. Other methods of crosslinking include γ-irradiation, electron
beam treatment, and physical crosslinking [63]. Physical crosslinking has been studied

	
  

	
  
	
  

17

extensively, especially for materials designed for medical device applications because
of its unique ability to control mechanical and diffusion properties of the hydrogel
without adding any additional harmful chemicals [63].
As mentioned in section 2.2, the DC bead is stabilized using chemical crosslinking. The
use of chemical crosslinking techniques has been noted as only being useful if toxic
reagents are completely removed following fabrication and before in vivo use [17].
However, this is often not possible as removal would result in instability or premature
release of the drug. Physical crosslinking is a method of crosslinking that uses low
temperature thermal cycling (LTTC) to induce physical changes within the structure of
the hydrogel by altering hydrogen bonding interactions. The material is exposed to a
low temperature, usually between -5 and -20°C, and then allowed to thaw to a higher
temperature, typically room temperature. These freeze-thaw cycles (FTCs), which can
be broken into several stages, result in phase separation, which forces the polymer
chains to form domains of structured crystallites. The resulting structure of the PVA
hydrogel is a matrix comprised of regions of crystallites – high polymer concentration,
and pores – low polymer concentration [64-66]. The end product is a solid gel, also
known as PVA cryogel [63]. Techniques including transmission electron microscopy
(TEM) [66], small angle X-ray scattering [66], and small angle and ultrasmall angel
neutron scattering [65,67] have been used to determine the micro and nanostructure of
PVA cryogels.
Several parameters are important in controlling the PVA hydrogel properties.
Molecular weight (MW) and PVA solution concentration are important in terms of the
resulting hydrogel structure [62,68-71]. An increase in molecular weight, and therefore
an increase in polymer chain length, results in an increase in the number and size of
crystalline regions [72]. An increase in the PVA concentration has been shown to result
in more stable gels with higher degrees of crystallinity and higher degrees of
crosslinking [72]. It has also been shown that higher PVA concentrations produce a
more rigid cryogel structure due to the increase in intermolecular hydrogel bonding
from the presence of more hydroxyl groups [73].
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In terms of processing, the number of FTCs, the upper and lower temperature limits,
and the rate of freezing and thawing can also be controlled to form different products
[62]. Through these methods, modifications can be easily made to control the diffusion
properties, which is important for drug delivery applications. The number of FTCs has
a significant effect on the structure and properties. It affects the dissolution of PVA
cryogels [74] as well as the mechanical properties, with an increase in stiffness
correlating to an increase in the number of FTCs [62], up to a maximum number of six
FTCs [75,76].
In terms of diffusion, which is highly relevant for drug delivery applications, PVA
cryogels have good diffusion characteristics that are highly tunable. The structure
comprised of approximately 3nm crystalline regions and 19nm amorphous regions [65],
which permit diffusion of certain molecules from the PVA matrix. Diffusion of solutes
is related to mesh size, which is related to crystallinity, and a size exclusion
phenomenon occurs [77]. The water diffusion coefficient can be adjusted as a function
of number of FTCs [78], with a decrease in diffusion resulting from an increase of
number of thermal cycles. This demonstrates the ability to tune the diffusion
characteristics to achieve optimal delivery of a particular molecule for a specific
application. These results are consistent with a study performed by our group. Using
bovine serum albumin (BSA) inside of a PVA matrix to study the effect of processing
parameters on protein release, it was found that the diffusion coefficients can be
modified over a 20-fold range with an decrease in release rate resulting from an
increase in the number of FTCs or an increase in the concentration of PVA [63]. The
use of chemically crosslinked PVA in current DEBs limits the ability to control
diffusion properties the way they can be controlled using physical crosslinking through
low temperature thermal cycling. This highlights a benefit of crosslinking the PVA
through freeze-thaw (FT) cycling.
Physically crosslinked PVA has been studied quite extensively as a biomaterial for use
in drug delivery. A common method of production of these PVA microparticles is
through the use of an emulsion technique. Ficek and Peppas prepared microparticles of
PVA for controlled delivery of proteins, modeled with BSA, through an emulsion
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technique and subsequent exposure to FT cycling. This novel work did not require the
use of a crosslinking agent because of the stabilization of the particles using freezethaw cycling [79]. Many other studies were undertaken using PVA as the drug carrier
for protein [80,81] or DNA encapsulation [82]. Work using a composite material with
PVA, such as chitosan or cellulose, has also been completed for drug delivery purposes
[83,84].
Poly(vinyl alcohol) treated through low temperature thermal cycling is known to be
biostable and nondegradable, with very low dissolution. For many applications in
medical devices, PVA hydrogels produced through physical crosslinking are
advantageous in this way because they can remain stable in the body over time. In
section 2.3.2 however, the degradability of microspheres was discussed in terms of its
importance for drug delivery purposes. It is important to look at the dissolution
potential of PVA hydrogels and how this can be enhanced in delivery systems.
Lozinsky et al. found initial swelling followed by shrinkage of PVA hydrogel beads
prepared through one FTC and subjected to water flow in a packed bead column for
two weeks. The overall result after two weeks was no net change in mass [85]. Hassan
et al. modeled the dissolution of crystallites in PVA films prepared by FT cycling and
showed that crystallite size was important for dissolution and smaller crystallites
dissolved quickly while those with a lamellar thickness greater than 215Å remained
stable over time [86]. Separately, they reported that PVA dissolution occurred for PVA
chains that were not incorporated into the crystalline structure formed during FT
cycling. It was found that the dissolving PVA was not from the crystalline regions and
polymer dissolution decreased as the number of FTCs increased. 15% PVA films of
low molecular weight (MW 35,740) were placed in 37°C water and a fractional
dissolution was observed to plateau at roughly 6 days. Samples subjected to three, five
and seven FTCs had dissolved fraction of approximately 0.48, 0.39 and 0.31
respectively. After six days, the polymer dissolution plateaued and the hydrogel was
stable, with some changes in swelling [72]. A study producing a multilaminate PVA
device for protein delivery also showed that an increase in the number of FTCs
decreased the dissolution of PVA. A fractional dissolution for 15% PVA samples (MW
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64,000) in water at 37°C over close to 100 hours showed a dissolved fraction of
approximately 0.13 and 0.05 for samples prepared with three and five FTCs
respectively [74].
Wong determined that after seven days in water or phosphate buffer saline (PBS), PVA
samples produced with six FTCs decreased slightly in mass. 10% PVA samples (MW
146,000-186,000) decreased to approximately a 0.88 and 0.83 fraction of their initial
mass in water and PBS respectively. It was reported that increases in PVA
concentration and the addition of nanofillers to the hydrogel decreased the mass loss
[87]. Willcox et al. found that aging increased the crystallinity of the hydrogel and
during storage at room temperature, sealed physically crosslinked PVA hydrogel
samples (19wt% PVA) lost between 8% of their mass (crosslinked using one FTC) or
12% of their mass (12 FTCs) through the expelling of water to the surface of the
hydrogel over one year [66].
Finally, the presence of salts has an effect on PVA hydrogel dissolution. Patachia et al.
reported mass loss of roughly 11% for PVA samples in 1M salt solutions with an
increase in mass loss occurring for higher electrolyte concentrations. Mass loss occurs
through the loss of water and was shown to reach equilibrium after roughly 25 hours in
salt solution [88].
Although biostability is important for many applications such as articular cartilage
replacement [89], or cardiovascular tissue replacement [62], it provides an interesting
problem for drug delivery applications as undesirable accumulation of the microspheres
could occur. This poses several problems, including potential toxicity. As well, it is
expected that for use in TACE therapy, accumulation in the arteries close to the tumour,
might actually inhibit further TACE administration, or would cause subsequent
infusion of microbeads to aggregate at distances further from the site of the tumour,
resulting in lower doses of chemotherapeutic agents to tumour cells and unwanted
administration of these drugs to surrounding tissue. It is important to look at how
degradability of DEBs can potentially be achieved, and specifically if we can
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accomplish this using PVA treated through LTTC because of the advantages this
material possesses for the application that we have presented.
2.5.2

Incorporated nano-elements

In this section, the nanoparticles that are incorporated into the poly(vinyl alcohol)
matrix will be discussed in terms of selection, properties, fabrication, and purpose in
the proposed drug delivery embolization system.
2.5.2.1

Iron oxide nanoparticles

Inorganic nanoparticles can be an excellent addition to materials for biomedical
applications because they provide the chemical and functional properties of the
inorganic component, while possessing the physical properties of the bulk material
[90]. Iron oxide nanoparticles have many properties that make them extremely useful in
biomedical applications such as cancer therapy and specifically, drug delivery.
Magnetite, Fe3O4, has an inverse spinel structure with oxygen forming a face-centered
cubic close packed arrangement. It is a specific form of iron oxide that is particularly
useful in biomedical applications because magnetite particles are biocompatible and
non-toxic, breaking down to eventually form blood hemoglobin [91,92]. Magnetite
nanoparticles can also have superparamagnetic properties, meaning they respond to an
external magnetic field, but do not hold magnetism once the magnetic field is removed.
The magnetic properties of iron oxide nanoparticles have made it useful for magnetic
targeting for localized or targeted therapy, as well as for enhancing contrast in magnetic
resonance imaging (MRI) [91]. They can be used as an MR contrast agent as they have
a strong impact on the T1 and T2 relaxation. T2 relaxation depends on the size and
coating of the particles [93]. They have also been studied for use as contrast agents for
X-ray and CT imaging [94]. Finally, an additional use for biomedical applications is
that they have also demonstrated the ability to induce hyperthermia in the presence of a
magnetic field, which can enhance tumour killing [91].
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Magnetite nanoparticles are easily produced in a co-precipitation method of ferric and
ferrous aqueous salt solutions in a molar ratio of 2:1, in the presence of hydroxide ions
[91,92,94]. The following is the overall reaction:
Fe2+ + 2Fe3+ + 8OH- à Fe3O4 + 4H2O

(1)

The coating of these nanoparticles with a biocompatible polymer, such as poly(vinyl
alcohol), has been shown to be useful in several ways. First of all, without coating, iron
oxide particles tend to agglomerate to form clusters [91]. Polymer coating can achieve
particle monodispersity and stable dispersions [95]. Finally, magnetite-loaded
polymeric particles are shown to have low cytotoxicity [96]. The co-precipitation of
aqueous ferric and ferrous iron salts in the presence of PVA was demonstrated by Zhou
et al. to fabricate iron oxide nanoparticle-containing magnetic PVA gel beads for
potential use as a drug carrier. The beads had excellent superparamagnetic property and
uniform size of 2mm diameter. The precipitation of the iron oxide nanoparticles was
described as forming a certain level of crosslinking within a PVA matrix [97].
Work on the interaction of PVA and iron oxide has been previously shown. Using
atomic force microscopy, Uner et al. demonstrated that a decrease in hydroxyl content
(increase in degree of acetylation) resulted in a significant drop in the adhesion force
between PVA and the iron oxide. Infrared spectroscopy data supported the notion that
increase in degree of acetylation resulted in increased intra and intermolecular
hydrogen bonding, leaving hydroxyl groups less available for adhesion with the iron
oxide surface [98]. Furthermore, Gonzalez et al. completed work on PVA ferrogels
produced through co-precipitation of iron salts in PVA, followed by freeze-thaw
cycling. They explained that the high affinity of PVA hydroxyl groups to oxide
surfaces led to adsorption of PVA onto iron oxide surfaces. A decrease in degree of
crystallinity and melting temperature was found in PVA ferrogels (containing
magnetite nanoparticles) compared to PVA hydrogels. The authors stated that the
decrease in crystallinity suggests that the formation of smaller crystalline regions as a
result of the nanoparticles interfering with the ability of PVA chains to form
crystallites. Additionally, a decrease in degree of swelling was found in PVA ferrogels.
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To explain this, they proposed that the total number of crystallites may actually be
increased with the presence of iron oxide nanoparticles, as the nanoparticles may be
nucleation centers creating low-mobility regions. These low-mobility regions are
essentially crosslinking points, and would therefore decrease swelling [99].
Alternatively, later work by Gonzalez et al. on PVA ferrogels prepared through initial
freeze-thaw cycling followed by iron salt loading and subsequent co-precipitation into
iron oxide showed an increase in degree of crystallinity and melting temperature. This
was said to be a result of an additional postcrystallization process from a second drying
step, as well as the presence of iron oxide nanoparticles creating a nucleating effect,
thus producing larger crystals [100].
The difference in the order of iron oxide precipitation and freeze-thaw cycling may
result in a slight difference in the material structure, but the notion that iron oxide
nanoparticles form crosslinks in PVA is consistent. This begs the question of whether
the subsequent removal of iron oxide nanoparticles from the PVA matrix would remove
crosslinks, and therefore allow dissolution of the material. This could be regarded as a
form of ‘degradable’ PVA iron oxide hydrogel. It will be further discussed in chapter 4.
Iron oxide has recently been incorporated into particles designed for embolization in
order to enhance contrast for various imaging modalities. Iron oxide incorporated into
tris-acryl microspheres [33,101] and chitosan microspheres [47,48,102] have been
produced for use as embolization particles detectable using MRI. With the use of CT,
iron oxide nanoparticle concentration of at least two orders of magnitude greater can be
detected than with 1.5 T MR. Concentrations of 1-40 mg Fe/mL was detected with CT
where 0.01-0.4 mg Fe/mL was detected with MRI. This has been suggested to be more
useful for specific applications, including magnetic hyperthermia where concentrations
of 1-10 mg Fe/mL are often used [103]. Based on the quantity of DEBs typically used
in DEB-TACE therapy, and the fact that they accumulate together in the vasculature of
tumour regions, it is worth investigating the use of CT to image iron-oxide containing
beads fabricated for this application.
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2.5.2.2

Bacterial cellulose nanocrystals

Bacterial cellulose (BC) is a biocompatible and non-toxic carbohydrate polymer [104].
It has been studied widely for use in biomedical applications such as wound dressings
[105] and reinforcement material for biomedical implants such as cardiovascular tissue
[76,106,107]. It is an ideal candidate due to its availability, biocompatibility, high
specific strength and modulus, hydrophilicity, high water holding capacity, and ability
to form a porous three-dimensional network. Furthermore, in its surface functionalized
form, it is an excellent material for drug conjugation in biomedical applications [108].
Cellulose is the most abundant naturally occurring polymer [109], with sources
including plant, algae, fungi and bacteria. Bacterial cellulose, synthesized by the
bacterium Gluconacetobacter xylinus bacteria, is advantageous for biomedical
applications because of its purity and high degree of crystallinity [110]. It is a high
molecular weight polymer composed of repeating units of two anhydroglucose units
with a reducing, and nonreducing end. Hydroxyl groups present in the equatorial ring
positions provide the high hydrophilicity and allow for functionalization [111].
It has been demonstrated that through several different reaction routes, BC can be
broken down quite effectively into cellulose nanocyrstals (CNC). This occurs as a
result of chemical reactions which hydrolyze the disordered (amorphous) regions of the
BC fibre, leaving the more ordered crystalline regions intact because they are better
able to resist hydrolysis [112]. The end product of these reactions is highly crystalline
cellulose in the nanoscale range. CNC has a very high surface to mass ratio [113],
which makes it a particularly useful carrier of drug molecules in high loading.
Many studies have reported methods of producing CNC from BC. These include
enzymatic hydrolysis, harsh acid hydrolysis, and ammonium persulfate oxidation.
Functionalization of the primary alcohol group on the BC or CNC has been
demonstrated through many reactions, producing both anionic and cationic surface
groups [114-116], with different types of conjugations of therapeutics being
demonstrated [117-119]. The well-established 2,2,6,6-tetramethylpiperidine-1-oxyl
(TEMPO) mediated oxidation reactions [120] introduces carboxylic acid groups to the
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surface, creating a negative surface charge, which allows positively charged drug
molecules to be loaded [121]. Alternatively, reactions such as the use of
epichlorohydrin and ammonium hydroxide [114], choline-based ionic liquid analogue
[122] or epoxypropyltrimethyammonium chloride [123] introduce cationic surface
charges to the cellulose fibres, providing means for the loading of negatively charged
drug molecules.
Because numerous chemical reactions can be performed on the surface to allow
different forms of drug conjugation, drug loading and release chemistry can be tailored
to the needs of a specific application. This makes it a very versatile material for a wide
range of drug molecules. The high potential drug loading, the ability to load different
types of drug molecules, and the ability to tailor drug release make CNC a good
candidate for improved drug loading and release in DEBs.
Of interest is the method using hydrogen peroxide to break the BC fibres down into
CNC while also oxidizing the surface to produce carboxylic acid groups [124]. This is a
facile method that provides a high surface area and high carboxyl functional group
content for loading of positively charged drug molecules, such as doxorubicin.

2.6 Proposed system
The system this thesis covers is a microbead comprised of a poly(vinyl alcohol) matrix,
loaded with iron oxide nanoparticles and drug-loaded cellulose nanocrystals. This
system, illustrated below in Figure 2.3, is a “nano-on-micro” drug delivery system. The
grey sphere illustrates the PVA matrix crosslinked through low temperature thermal
cycling process in conjunction with iron oxide precipitation. The black dots represent
the iron oxide nanoparticles distributed throughout the PVA matrix. The black curved
lines illustrate the incorporation of CNC and the red ovals represent the potential to
load therapeutic molecules onto CNC within the microbead.
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Figure 2.3 Proposed multifunctional nano-on-micro system
The system is hypothesized to be beneficial for use as a drug delivery embolization
particle in TACE therapy based on the following reasons: the potential drug loading
and release capabilities due to the presence of functionalized CNC; the ability to
visualize it using clinical imaging techniques as a result of iron oxide nanoparticle
incorporation; the potential for magnetic targeting to a specific location making use of
the magnetic properties of iron oxide; and the potential for elimination due to
dissolution of the polymer matrix resulting from the degradation of iron oxide
nanoparticles.

2.7 System assembly
2.7.1

Microbead fabrication

This portion of the literature review section covers the topic of microbead production,
as the fabrication of our microbead system is a significant part of the work described in
this thesis.
Polymer microspheres or microparticles can be fabricated using many different
techniques. These include interfacial polymerization methods such as suspension
polymerization, emulsion polymerization and dispersion polymerization; emulsionsolvent

extraction/evaporation;

extrusion

methods;

photolithographic

and

micromolding methods; and spray drying techniques [16,125]. There are, however,
downsides to each of these techniques, with the main problem being difficulty in size
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control resulting in particle polydispersity. This has led us to an alternative approach –
the use of microfluidic technology.
The ability to control bead size is of high importance. Not only are specific bead
diameters more advantageous for the application described in this work, but is has also
been suggested that further work should be done to tailor the DEB size to the arterial
anatomy of the tumour site [15]. This requires a production method with a great degree
of control over microbead size. The desirable size to be fabricated for this application is
roughly 100-200µm in diameter. This range of beads have been fabricated using
numerous microfluidic techniques and with various materials [126-128].
The use of microfluidics to form emulsions has been explored to produce complex and
highly monodisperse particles. Particles of various structures, morphologies, and sizes
ranging from nanometers to hundreds of micrometers can be fabricated [126].
Microfluidic devices consist of microchannels, usually around 10-100µm [129-131],
through which, in many cases, immiscible phases flow and interact. At the junction
between these channels, droplets of one phase are formed. This is called the dispersed
phase, with the other liquid being the continuous phase. By controlling parameters such
as flow rate, the size of the dispersed phase droplets can be modified [131-133].
Common microfluidic systems are either composed of glass capillary tubing, or
microchannels etched into a polymer such as poly(dimethyldisiloxane) (PDMS).
Channels can be set up into various configurations including cross-flow, co-flow or
flow-focusing configurations in which the continuous and dispersed phases either flow
alongside or against each other [134]. Other considerations in the design of a
microfluidic system include the placement and location of channels, the interactions of
the fluids with the wall, the size and shape of the desired particles, as well as the
activity of the therapeutic molecule [131,133].
This approach will be used for the production of our multifunctional nano-on-micro
system and will be described in detail in the following sections.
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2.7.2

Drug loading and release

The incorporation of CNC within the microbead provides a good route for drug
conjugation. CNC can be produced through hydrolysis, with oxidation of the alcohol
groups of the cellulose surface occurring. At the proper conditions, oxidized cellulose
has been shown to be able to load peptides or drugs containing a positive charge. Spaic
demonstrated the loading of benzylamine, a model for doxorubicin, to the BC fibres
[121].
With the proper investigation and analysis of CNC functionalization, we can achieve
loading of drugs like doxorubicin onto the fibres. Dox contains a primary amine group,
which when protonated, will conjugate to deproponated carboxylic acid groups of the
CNC.

2.8 Conceptual application
The conceptual application of this system follows a similar procedure to the one
currently used with DEBs. The therapeutic molecule, doxorubicin, would be loaded
into the prepared microbeads. Microbeads would then be delivered by catheter into the
tumour site. Visualization of the particles could be completed in real-time as well as
following therapy. Drug release would occur and the microbead matrix would
disassemble and be cleared from site, to allow repeat treatment.
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CHAPTER 3 – Multifunctional Microbeads

3.1 Introduction
This chapter describes the design and fabrication of a microfluidic device for the
production of microbeads, followed by microbead fabrication and characterization. A
flow-focusing configuration was selected for the microfluidic device, optimization of
conditions used for microfluidic microbead production was performed, and microbeads
composed of PVA, iron oxide nanoparticles, and CNC were produced. Microbead
characterization was undertaken to determine size, structure, and composition. In this
work, we also briefly investigate the magnetic properties and visualization capabilities
of the microbeads produced.

3.2 Materials and methods
All chemicals used were ACS reagent grade and purchased from Sigma-Aldrich.
Distilled water was used for all experiments. Bacterial cellulose was synthesized in the
laboratory according to the procedure outlined in Appendix I. Bacterial cellulose
samples were converted into CNC using a hydrogen peroxide hydrolysis reaction
procedure developed by another member in our research group and were provided to
me for implementation in my work. CNC with a width of approximately 20nm and
length ranging between 100 and 2000nm were used.
3.2.1 Solution preparation
Four different solution compositions have been used throughout this study to produce
microbeads, and are outlined in Table 3.1.
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Table 3.1 Dispersed phase solution composition
Solution Identification

Composition

1

Low iron PVA

2

High iron PVA

3

High iron PVA CNC

4

High iron PVA CNC-10

5wt% PVA + 1wt% FeCl3 + 0.6wt%
FeCl2•4H20wt% in water
5wt% PVA + 3.1wt% FeCl3 + 1.9wt%
FeCl2•4H20wt% in water
5wt% PVA + 3.1wt% FeCl3 + 1.9wt%
FeCl2•4H20wt%+ 1wt% CNC in water
5wt% PVA + 3.1wt% FeCl3 + 1.9wt%
FeCl2•4H20wt%+ 10wt% CNC in water

To produce these solutions, poly(vinyl alcohol), MW 146,000-186,000, 99+%
hydrolyzed, was dissolved into a quantity of water making up 80wt% of the total final
solution. This was heated to 90°C for approximately 3 hours, or until complete
dissolution. Separately, iron (III) chloride (FeCl3) and iron (II) chloride tetrahydrate
(FeCl24H20) (in a 2:1 molar ratio of Fe3+ to Fe2+) were weighed out and added to water
(comprising the remaining water quantity required for final solution composition
outlined in Table 3.1). This was mixed with a magnetic stirrer for several hours. The
PVA solution, after cooling, was added to the iron chlorides solution and mixed with
magnetic stirring. The final solution was filtered through a 5µm filter (Acrodisc syringe
filter with Versapor Membranes) to ensure any suspended impurities were removed.
For solutions 3 and 4 in Table 3.1, cellulose nanocrystals (CNC) were incorporated. To
do this, wet CNC was weighed out to the desired amount and added to the prepared
solution of PVA and iron chlorides in water. The resulting solution was sonicated with
an ultrasonic probe (Q Sonica Sonicator ultrasonic processor) for 1 minute at 120W.
The solution was mixed with a magnetic stirrer prior to use.
The solution compositions that were determined to be best were the high iron PVA
solution (Table 3.1 solution 2) and the high iron PVA CNC solution (Table 3.1 solution
3). These were used as the microbead compositions for the following experiments. The
exception to this are those used for scanning electron microscopy (SEM) images,
energy dispersive X-ray spectroscopy (EDX), and part of the CT experiment, which
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were performed on microbeads fabricated using the low iron PVA solution (Table 3.1
solution 1).
3.2.2

Microchannel device fabrication

The design and fabrication of a custom-designed microchannel device was necessary
for microbead production. Microchannels were milled out of poly(methyl methacrylate)
(PMMA), assembled with another slab of PMMA and connected with screws. 0.038”
outer diameter tubing (Intramedic polyethylene tubing, BD) was connected to the outlet
hole. 20 gauge stainless steel needles (Hamilton Company) were connected to the
inlets, and attached to syringes using 0.125” outer diameter silicone tubing (Cole
Parmer) and standard luer lock (Cadence Science). A 10mL syringe was filled with the
continuous (oil) phase solution and a 1mL syringe was filled with the dispersed (PVA
iron) phase solution. These syringes were loaded onto micropumps (NE-1000, New Era
Pump Systems Inc.) and the flow rates controlled. A microchannel device and the entire
experimental set up is shown in Figure 3.1. Further details of the microchannel devices
and the final design choice used for microbead production is described in section 3.3.
A

B
Inlet
needles

Outlet
tubing
	
  

Figure 3.1 A) Custom-designed microchannel device. B) Microchannel production
experimental set up.
3.2.3 Microbead production
The channel and system was set up as shown in Figure 3.1. The solutions listed in
Table 3.1 were used to produce microbeads through the custom-designed microchannel
device. The continuous and dispersed phases flowed through the device to form
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dispersed phase solution drops. At the outlet, they fell into a sodium hydroxide (NaOH)
solution whereby the PVA-containing dispersed phase solution droplet solidified,
forming microbeads. Images of the beads flowing through the microchannel device
were taken using a high-speed camera (Redlake MotionScope M with frame rate up to
1000frames/sec). Solution flow was maintained until steady state was reached (~5min)
before sample collection. The beads were further washed with 50v/v% ethanol in water
several times. These samples were then subjected to one FTC. This was completed
either in a -20°C freezer overnight followed by thawing to room temperature or in a
water bath with controlled temperature (0.1°C/min to -20°C, held for one hour at
-20°C, 0.1°C/min to 20°C).
3.2.4 Optical microscopy
Images were taken for characterization and size analysis of the microbeads using
optical microscopy (Olympus BX60). Images were taken with a OMRX A35100U
camera attachment to the microscope and the area of the beads were measured using
Image J software particle analyzer function for over 100 samples. This data was then
converted into an equivalent spherical diameter. Statistical analysis was performed on
the mean equivalent spherical diameters using an unpaired t test, and a p-value of
< 0.05 was considered significant (GraphPad Prism).
3.2.5 Scanning electron microscopy
SEM was performed on the microbeads to characterize the structure and morphology of
the surface. Microbeads beads were dehydrated through to 100% ethanol by
incrementally increasing ethanol concentration. Critical point drying (Samdri PVT-3B)
was performed on the microbeads suspended on filter paper. Microbeads were loaded
onto a p type silicon wafer with 0-10 Ohm-cm resistivity and an orientation of 100
(University Wafers), and subsequently coated with osmium (OPC-60A Osmium Plasma
Coater). Images were taken with a scanning electron microscope (LEO (Zeiss) 1540XB
FIB/SEM).
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3.2.6 Energy dispersive X-ray spectroscopy

EDX is a technique used for elemental analysis of a given sample. EDX (LEO (Zeiss)
1540XB FIB/SEM) was performed on the samples prepared for SEM described in
section 3.2.5.
3.2.7

Transmission electron microscopy

To characterize the internal composition of the microbeads, transmission electron
microscopy (TEM) was performed. Beads fabricated using the high iron PVA solution
(Table 3.1 solution 2) were dehydrated in acetone and then embedded in an EponAlardite epoxy resin (3.5mL Araldite 502, 4.5mL Epon 812, 18mL DDSA, 0.67mL
DMP). This was completed by the submergence of beads in incrementally increasing
concentrations of acetone, acetone and epoxy resin, and finally, kept overnight in 100%
epoxy. Following this, beads in epoxy were heated in an oven at 60°C overnight in
plastic molds. Samples were ultramicrotomed (Reichert-Jung Ultracut E) with an
ultrafine diamond knife to a thickness of 70nm and placed on Formvar carbon-coated
100 mesh copper grids (Electron Microscopy Specialists). The samples were examined
under TEM using a Philips TEM (CM-10.s). Iron oxide nanoparticle size was measured
using Image J software. Based on the images selected for measurement, an intensity
threshold between 0 and 80 was selected to differentiate the particles from the
background, and the particle analyzer function was then used to measure particle area.
This was converted into an equivalent spherical diameter. (See Appendix IV for images
used in this measurement).
3.2.8 X-ray diffraction
To identify the crystalline material present in the microbeads, X-ray diffraction (XRD)
was performed. Beads fabricated with the high iron PVA CNC solution (Table 3.1
solution 3) were dried at 60°C overnight and placed on a glass slide with double sided
tape. XRD analysis was performed using a Rigaku-Rotaflex Diffractometer (RU200BH) with a Co-kα radiation (λ =1.79 Å) at 30kV and 44mA. Spectra with a 2θ
diffraction angle were scanned from 0° to 82° with a 0.2° step size. A background scan

	
  

	
  
	
  

45

was performed on the blank slide with tape, and the relative peaks were subtracted from
the sample peaks. Spectra were plotted for a 2θ of 10° to 82°.
3.2.9 Clinical computed tomography
Computed tomography of microbead samples was performed in order to determine the
visibility of the multifunctional microbeads under clinical imaging techniques.
Microbeads produced using the low iron PVA solution (Table 3.1 solution 1) and the
high iron PVA CNC solutions (Table 3.1 solution 3) were used. Additionally, 5wt%
PVA solution processed as a film using LTTC (see section 4.2.2 for preparation
procedure) was imaged as a control. These control films were homogenized
(Brinkmann Homogenizer Polytron PT 10/35) on high speed to produce small pieces.
Various quantities of microbeads and equivalent quantities of plain PVA samples were
weighed out and suspended in phosphate buffer saline (PBS) solution and contained
within 1.5mL microcentrifuge tubes. These tubes were held in a tube rack and placed
within the scanner. Samples were imaged using clinical CT (GE Healthcare Discovery
VCT). Axial scans were completed with a rotation time of 0.4 seconds using a bone
reconstruction scan type. Conditions were set to 80 kV, 300 mA, and a slice thickness
of 0.625mm. Two different window width (W) (Hounsfield units) and level (L)
(Hounsfield number) settings were used to view the images: W/L of 426/183 and
650/100.
3.2.10 Acid/base titration of cellulose nanocrystals
To measure the carboxyl content on the CNC, an acid/base titration was performed.
0.1g wet CNC was weighed out and dispersed into 10mL 1mM hydrochloric acid (HCl)
solution using an ultrasonic probe (Q Sonica Sonicater ultrasonic processor, Newton,
CT) for 30 seconds at 120W. 1mM NaOH was titrated against the solution containing
CNC and the curve was plotted. This was repeated in triplicate. The same procedure
was performed on a sample of the BC used as the reactant for the conversion to CNC.
Additional washes with dilute acid and water were performed on the BC sample before
titration to ensure any residual NaOH from BC harvest and separation was neutralized
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and removed. The carboxyl content of the CNC was calculated using Equation 2. The
wet CNC contained 99% water and therefore, an equivalent dry mass of 1% of the wet
mass was used. Finally, the pKa of the CNC was determined based on pH at the halfequivalence point according to the Henderson-Hasselbalch equation. For comparison,
these results were plotted against a titration curve of 1mM NaOH against 1mM HCl.
𝐶𝑎𝑟𝑏𝑜𝑥𝑦𝑙  𝑐𝑜𝑛𝑡𝑒𝑛𝑡   𝑚𝑚𝑜𝑙/𝑔𝐶𝑁𝐶 =

𝑣𝑜𝑙𝑢𝑚𝑒  𝑜𝑓  1𝑚𝑀  𝑁𝑎𝑂𝐻  𝑡𝑜  𝑛𝑒𝑢𝑡𝑟𝑎𝑙𝑖𝑧𝑒  (𝐶𝑁𝐶−𝐵𝐶)
𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡  𝑑𝑟𝑦  𝑚𝑎𝑠𝑠  𝑜𝑓𝐶𝑁𝐶

(2)

3.3 Results and Discussions
3.3.1 Microchannel device design and microbead production
The overall design of the microbead production method is shown below in Figure 3.2.
It consists of a continuous phase (oil phase) flowing against a dispersed phase (PVA
iron phase) and meeting at a junction, which is the site of the formation of microbeads
comprised of the dispersed phase solution. The microbeads are subsequently dropped
into a high pH (sodium hydroxide) solution where iron oxide precipitation occurs
within the PVA matrix. Following this, thermal cycling is performed to induce physical
crosslinking in the PVA.
Continuous phase
Dispersed
phase

Microchannel
system

0.5 M NaOH

Low temperature
thermal cycling

Microbead
formation

Iron oxide
precipitation

Physical
crosslinking

Figure 3.2 Production process for PVA iron oxide CNC microbeads.
Several designs were tested for the microchannel system used for production of 100200µm diameter PVA iron oxide CNC microbeads. Initial designs using a T-junction
microchannel configuration were used and results were unsatisfactory (details are
collected in Appendix III). The final design selected made use of a flow-focusing
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microchannel configuration (Figure 3.3). Dispersed phase (PVA iron phase) flow is
directed through a channel by the continuous phase (oil phase) flowing from two
directions. The two phases are forced through a small opening, causing a viscous stress
action of the continuous phase on the dispersed phase [1]. This results in the pinch-off
of the dispersed phase, forming droplets. Compared to a T-junction microchannel
configuration, we found that the flow-focusing system minimized the interaction
between the dispersed phase and the channel wall, thus preventing the formation of
slugs – elongated droplets [2] – of the dispersed phase in the channel. Adherence of the
dispersed phase to the wall inhibits bead production, and is a common issue [3]. The
use of a flow-focusing system addresses this issue, with another option being the
coating of channel walls to make it immiscible with the dispersed phase (ie.
hydrophobic coating for an aqueous dispersed phase) [3].
Continuous phase inlet

Dispersed
phase
inlet

Outlet

	
  

Figure 3.3 Flow focusing microchannel design. Red channel width is 200µm. Blue
channels have a width of 500µm with a narrow section of 127µm.
Optimization of several key parameters was undertaken. Table 3.2 outlines the
parameters and conditions that were varied. Under optimized conditions, the droplets of
dispersed phase solution formed at the junction of the two phases was smaller than the
width of the channel. This is consistent with reports that flow-focusing systems are
advantageous in their ability to produce microparticles of smaller sizes relative to other
channel configurations, such as the T-junction [4,5]. Images of the formation of a
microbead at the junction of the PVA iron phase and the oil phase is shown in Figure
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3.4. At the junction of the channels, the dispersed phase is constricted through the
channel by the continuous phase, where droplets are formed.
	
  

Figure 3.4 Microbead production using the flow-focusing microchannel design.
The red arrow indicates flow of the dispersed phase (Table 3.1 solution 3) and the
blue arrow indicates flow of the continuous phase (Table 3.2 continuous phase
composition 5).
Table 3.2 Microbead production process variable parameters
Parameter

Conditions

Continuous phase
composition

1. hexane
2. 1wt% Span80 in hexane
3. 1wt% Span80 + 49.5wt% mineral oil in hexane
4. undecane
5. 1wt% Span80 in undecane
See solutions 1-4 in Table 3.1

Dispersed phase
composition
Flow rates
Collecting reservoir
composition
Collecting reservoir
temperature

Continuous phase: 10-25mL/h
Dispersed phase: 0.1-2mL/h
1. 0.5M NaOH in water
2. 0.5M NaOH + 50v/v% ethanol in water
-20°C to room temperature

The most favourable conditions for reproducible production of 100-200µm diameter
microbeads were found. A continuous phase composed of 1wt% Span80 in undecane
(Table 3.2 continuous phase composition 5) was selected. This was chosen based on a
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match in viscosity of the undecane. The interaction of the dispersed and continuous
phases, based on viscosity and interfacial tension, is an important factor. It has been
reported that selection of a more viscous continuous phase allows better droplet
formation [3]. This is consistent with our findings, as continuous phases containing
undecane were more effective than those containing hexane. The wetting property of
the fluids with the microchannel wall is also an important parameter. We found that the
use of Span80 surfactant allowed more effective bead production. Xu et al. used a
similar microchannel system composed of PMMA, and found that with the addition of
Span80 to the immiscible phase, the PMMA surface was converted from partially
hydrophilic to completely hydrophobic. Based on this, they added 0.1-2wt% Span80 to
a continuous oil phase to produce better droplets of a dispersed water phase using the
microchannel system [6].
Optimal flow rates were also determined for our system. The continuous phase flow
rate was maintained between 20 and 22mL/h and the flow rate of the dispersed phase
was always kept at 1mL/h. These are similar flow rates to other work producing beads
of a similar size range [6,7]. The collecting reservoir composition used was 0.5M
NaOH in 50v/v% ethanol in water at room temperature.
3.3.2 Microbead characterization
Following iron oxide precipitation, bead collection, separation, and one FTC, images of
the microbeads were taken, and an example is shown in Figure 3.5. It is clear that the
shape of the microbeads is not spherical. This is suspected to result from the high
viscosity of the solution used. The solidification process for the beads, involving iron
oxide precipitation and reduced solubility of PVA in NaOH, is so fast that the beads
retain a teardrop shape. Variations in the distance of the outlet tubing to the sodium
hydroxide collecting reservoir as well as reservoir temperature did not result in a
change in the microbead shape. The equivalent spherical diameter was calculated to be
111.4 ± 39.4µm.
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Figure 3.5 A) Optical image of microbeads fabricated using high iron PVA
solution (Table 3.1 solution 2). B) Histogram of microbead equivalent spherical
diameter fit to a Gaussian distribution.
The obtained microbead size is desirable for our application, as beads of around 100µm
can be easily administered by catheter and microbeads in this size range have been
shown to reach the distal portions of a tumour and adequately occlude the tumour
vessels [8,9,10]. However, the uniformity of these particles could be improved.
Although microfluidics is a favourable approach to accomplish the production of
monodisperse particles, we see a range of the resulting microbead equivalent spherical
diameters. This could be due to non-optimized materials comprising the microchannel
device, which result in undesirable interactions with the dispersed or continuous phases.
Alternatively, there may be need for further optimization of the solution used as the
continuous phase.
The shape of the particles must also be considered. Some irregularly shaped
embolization particles have been used, such as Contour™ PVA embolization particles
[11], which indicates that the microbeads we have produced may be suitable. However,
it has been suggested that spherical microparticles can reach more distal locations and
result in a more complete blood vessel occlusion than irregular materials or material
with irregular shape [12,13]. Nevertheless, the microbeads we have produced are
uniformly shaped, as a droplet shape is consistently seen. These may perform better

	
  

	
  
	
  

51

than non-uniformly shaped particles. An additional argument for the use of uniformly
shaped particles is a consistently calibrated drug loading [13]. We expect that drug
loading consistency can be achieved for the microbeads produced here. Through the
mechanism we propose for drug loading, which uses CNC to conjugate drug molecules,
there exists the potential for highly uniform drug loading.
The successful production of microbeads comprised of PVA and iron oxide
demonstrates the design, fabrication, and application of a flow-focusing microchannel
system. To the best of our knowledge, this is the first report of microbeads of the
current composition and dimension. Preparation of iron oxide containing PVA beads
with a diameter of 2mm has been shown [14]. This was accomplished through the
dropwise addition of iron salts and PVA solution into alkaline solution through the use
of a syringe fitted with a needle. Although this method is simple and produces beads of
uniform size, they are too large to be useful for most drug delivery applications and are
significantly larger than DEBs. We attempted the approach described by Zhou et al.
and were unable to reduce bead diameter to below 1mm. Even through the reduction of
needle gauge size, beads of applicable dimension could not be produced as a result of
the surface tension present in the solution dropping from the needle tip. Through this
experience, we chose to pursue the use of a microchannel device for the preparation of
100-200µm diameter microbeads. Our approach using microfluidics is advantageous in
its ability to produce small diameter microbeads.
CNC containing PVA iron oxide microbeads were also prepared using the flowfocusing microchannel. Conditions and procedure similar to that of the PVA iron oxide
beads were used and the product microbeads are shown in Figure 3.6. With
incorporation of CNC at 1wt% (Table 3.1 solution 3), we do not see a large difference
in the morphology and size of the microbeads compared to microbeads without CNC.
The average equivalent spherical diameter of the microbeads containing 1wt% CNC is
108.2 ± 41.4µm. There is no statistically significant difference in the equivalent
spherical diameters of the beads without CNC compared to those containing 1wt%
CNC. This suggests that at this loading of CNC, there are no major alterations in the
preparation procedure, or disruption to the size and uniformity of the microbeads.
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However, when a large increase in the CNC loading was attempted using a solution
with 10wt% CNC (Table 3.1 solution 4), we saw a substantial increase in microbead
size (~600µm) and there was difficulty in production. This suggests that there is an
upper limit to the amount of CNC able to be incorporated using this approach for our
desired size range. Increasing CNC loading is expected to increase the system viscosity,
which may hinder formation of 100-200µm microbeads.
PVA Iron Oxide CNC Beads
Equivalent Spherical Diameter
Relative frequency (%)

25
20
15
10
5
0

0

100
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300

Diameter (um)

Figure 3.6 A) Optical image of microbeads fabricated using high iron PVA CNC
solution (Table 3.1 solution 3). B) Histogram of microbead equivalent spherical
diameter fit to a Gaussian distribution.
SEM was performed on microbeads and these images are shown below in Figure 3.7.
Figures A and B display the whole collapsed beads, and Figures C and D illustrate the
surface morphology of the microbeads. The difference in size compared to the
measurements described above is a result of the dehydration process used prior to
imaging. Shrinkage occurred due to the removal of water. EDX was performed on the
microbead (Figure 3.8) and the results confirm the presence of iron as a component of
the bead.
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Figure 3.7 SEM images of PVA iron oxide microbeads of approximately 40µm
diameter. Microbead size and shape is a result of the dehydration process.
Figures A and B show whole beads and figures C and D display surface
morphology.
A	
  

B	
  

	
  
Figure 3.8 EDX spectrum of PVA iron oxide microbeads. A) Whole microbeads
with a square specifying the location of EDX sampling. B) Spectrum indicating the
presence of iron in the microbeads.
Transmission electron microscopy images were taken of microtomed microbead
samples. The iron oxide nanoparticles are very clearly displayed (Figure 3.9). There are
several important aspects to consider when interpreting this result. First of all, the size
of the nanoparticles is important. For use as a magnetically targeted drug carrier or
imaging contrast enhancement agent (MRI and CT), nanoparticles must have high
magnetization values, size of less than 100nm, and a narrow particle size distribution
[15]. The nanoparticles that we see in the PVA matrix were found have a mean
diameter of 28.0 ± 20.6nm, which fit the size requirements (see Appendix IV for size
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distribution). The large standard deviation is a result of some aggregates of two
nanoparticles, and in rare cases, aggregates of more than two nanoparticles. Figure 3.10
shows examples of these aggregates. Although aggregation is minimal, the measured
particle size and standard deviation is larger than it would be for only single
nanoparticles due to the inclusion of aggregates in the size measurement.

Figure 3.9 TEM of PVA iron oxide microbead interior.

	
  

Figure 3.10 TEM of PVA iron oxide microbead interior. The black arrow
indicates an individual iron oxide nanoparticle, the blue arrow indicates an
aggregate of 2 nanoparticles, and the red arrow indicates an aggregate of multiple
particles.
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Secondly, and arguably of more importance, is the distribution of the iron oxide
nanoparticles within the PVA matrix. Aggregation of iron oxide nanoparticles is a
common problem that exists due to interactions between particles. When aggregates
form, magnetic dipole-dipole attractions occur between them and ferromagnetic
behavior results [16,17], which is less desirable than superparamagnetic behavior for
biomedical applications. In our case, aggregation is not a serious problem.
The low level of iron oxide nanoparticle aggregation can be understood in terms of the
particle formation process. In the current process, Fe2+ and Fe3+ are uniformly
distributed in the matrix of the PVA microbeads. Iron oxide is formed by in situ
precipitation within the liquid PVA hydrogel matrix by diffusion of NaOH into it. The
viscosity of the PVA solution hinders the movement of the iron oxide nuclei and limits
their growth. As the PVA beads are solidified using the LTTC process, the iron oxide
nanoparticles are immobilized in space within the hydrogel matrix of the microbeads,
leading to the small size and low level of aggregation observed. The clusters of multiple
nanoparticles are most likely formed by nucleation independently, due to local
concentration fluctuations of iron chlorides, rather than due to an aggregation process.
Coating of iron oxide nanoparticles with PVA has been reported in the literature to
result in monodisperse particles without aggregation [15,18,19], and the PVA acts as a
stabilizing agent in ferrofluids [20]. In one study where iron oxide precipitation was
completed in aqueous PVA, it was suggested that PVA can bind irreversibly to the
magnetite surface [21]. In work by Gonzalez et al., magnetite nanoparticles of less than
50nm in size were produced in PVA films through a similar process – the coprecipitation of iron salts in PVA followed by physically crosslinking. Low levels of
aggregation were also observed. It was hypothesized that adsorption of PVA to the
magnetite surface through the interaction of the PVA hydroxyl groups with iron oxide
controls the growth and aggregation of nanoparticles [22].
To characterize the nature of the iron oxide nanoparticles, XRD was performed on a
dried microbead sample made form the high iron PVA CNC solution (Table 3.1
solution 3). The low signal to noise ratio of the XRD pattern shown in Figure 3.11A is
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due to the limited sample size used. Since PVA is a polymer of limited degree of
crystallinity, its XRD pattern is more ill defined and stretches over a broad 2θ range.
This also limits the signal to noise ratio and identification of other Fe3O4 diffraction
peaks. However, certain characteristic peaks are visible, which justifies the presence of
PVA and iron oxide in the form of magnetite (Fe3O4). The diffraction peak
corresponding to Fe3O4 can be identified by comparing to a standard XRD pattern for
magnetite (International Centre for Diffraction Data (ICCD) card number 00-019-0629
from PDF-4+ software) (Figure 3.11B). Additional information is presented in
Appendix II. The most intense peaks for magnetite occur at 2θ values of 35°, 41°, and
74°. In the XRD for the microbeads produced in this work (Figure 3.11A), we see a
significant peak occurring at 22°, which corresponds to PVA, consistent with our data
in section 4.3.1 (Figure 4.2) and literature reports [23,24]. There are also three main
peaks at 33°, 41°, and 74°, consistent with characteristic magnetite peaks. There is
slight shift in location and relative intensity of the first peak, at 33°, compared to the
standard magnetite sample, at 35°. This is probably due to the small sample size,
resulting in a highly noisy pattern. Alternatively, there may be slight change in the
crystal structure of the iron oxide in the microbeads compared to a standard magnetite
curve. However, we compared the microbead diffraction pattern to that of another
possible resulting form of iron oxide – maghemite – and the peaks do not align. Given
the proximity of the microbead diffraction peaks to a standard magnetite pattern, we
can conclude that magnetite is likely the form of iron oxide present. Microbead
production using a similar method is consistent with this result [14]. Furthermore, our
results coming up in section 4.3.1 for a film of the same composition very clearly
illustrate the presence of magnetite. No specific peak is detected for CNC because the
relative composition is very low.
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A	
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Figure 3.11 A) XRD pattern of PVA iron oxide CNC microbeads. B) ICCD card
for magnetite (number 00-019-0629).
Magnetite occurs in an inverse spinal structure with both ferrous and ferric ions and
oxygen. Magnetite, depending on nanoparticle size, is superparamagnetic, meaning that
it does not retain magnetism after the magnetic field is removed. The presence of iron
oxide nanoparticles in the form of magnetite is promising for future work in magnetic
targeting of these microbeads or use in magnetic resonance imaging. Zhou et al.
demonstrated

that

the

2mm

PVA

iron

oxide

beads

they

produced

had

superparamagnetic properties [14]. Vibrating sample magnetometer measurements
were attempted on our microbead samples, but due to sample size limitations, reliable
results could not be obtained. Instead, we investigated the effect of an external
magnetic field on these microbeads.
In the presence of a strong magnet, we are able to visually demonstrate the magnetic
properties of the beads. Microbeads composed of high iron PVA CNC solution (Table
3.1 solution 3) were suspended in PBS and an external magnetic field was applied
using a strong permanent magnet. Images were taken of the microbeads movement
towards the permanent magnet and their settling upon removal of the magnetic field as
shown in Figure 3.12. Qualitatively, this demonstrates the ability to mobilize and locate
the microbead using an external magnetic field. Further work in this area should be
completed to better investigate magnetic properties as there could be great potential for
this system to be used for magnetic localization.
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Suspended beads

Magnet introduced

All beads are located
at the magnetic field

Magnet removed

Complete settling
due to gravity

Figure 3.12 Movement of PVA iron oxide microbeads towards a permanent
magnet.
3.3.3 Microbead visualization
The ability to visualize this class of microbead using clinical CT was demonstrated on
beads of low iron oxide loading in PVA (Table 3.1 solution 1). Microbeads were placed
in PBS solution in tubes and imaged. What can be seen in Figure 3.13A is suspension
containing a small quantity of microbeads at the bottom of the tube. The 40mg quantity
of beads is understandably more visible than 20mg of beads, due to the presence of a
greater amount of Fe3O4-containing particles. However, it is difficult to detect the
enhanced contrast in either sample. Figure 3.13B is the same image processed using
different settings of the window width and level of the CT machine. At this contrast and
sensitivity, we are better able to visualize the presence of the higher contrast
microbeads at the bottom of the tubes. However, this contrast is weak, and unlikely to
be sufficient for practical use, as the microbeads appear very similar to the PBS control,
even when accumulated at the base of the tube. In order to enhance the contrast, a
larger quantity of iron was added to the solution for microbead preparation.
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Figure 3.13 CT images of low iron PVA microbeads at quantities of 40 and 20 mg.
A) and B) represent different window/level settings of the CT machine (W/L of
650/100 (A) and 426/183 (B)).
Subsequent CT experiments were performed using microbeads of the higher iron oxide
loading and containing CNC (Table 3.1 solution 3). These beads, at loading levels of
11-50mg in PBS, were imaged using CT. Results are shown in Figure 3.14A. Since
cellulose is of similar elemental composition as PVA, it is not expected to contribute to
any CT contrast. At similar bead loadings, an enhanced contrast can clearly be seen
compared to the microbeads shown in Figure 3.13. The amount of iron loading in
microbeads is an important factor in the level of visibility, and at the higher
concentration of iron, we are able to see increased contrast. The samples in Figure
3.14B contain the same quantities of sample, but are plain PVA samples containing no
iron oxide, and used as a control. We are not able to visualize any contrast enhancement
in these samples thus confirming the positive effect of iron oxide in CT imaging. It can
be concluded that the PVA iron oxide CNC microbeads provide improved visualization
compared to plain PVA samples and that greater amounts of iron result in greater
contrast.
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Figure 3.14 CT images of 50, 25 and 11mg quantities of sample. A) Tubes contain
microbeads fabricated using the high iron PVA CNC. B) Tubes contains control
samples of plain PVA. (W/L of 650/100).
Figure 3.14 illustrates the ability to detect the high iron PVA CNC microbeads relative
to PBS under CT. The lowest quantity of beads does become harder to differentiate
from the fluid, which leads to the conclusion that some accumulation of beads is
necessary to result in a high enough contrast for adequate detection. For clinical
applications in TACE therapy, 1-4mL of microbeads is typically used [11]. For
volumes such as this, and given that accumulation of beads does occur, the level of
contrast enhancement we are seeing from small quantities of beads may be appropriate.
Of course, work demonstrating the use of these microbeads in vivo would need to be
completed to properly assess this. Not only is PBS not equivalent to tissue, but also, the
level of accumulation of beads in the vasculature is an important factor in determining
whether these microbeads would be visible. Nevertheless, the ability to detect these
microbeads in PBS using CT has been demonstrated, and this preliminary work
encourages further studies using this system.
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In the imaging of Lipodiol-loaded PVA microspheres with CT, the researchers were
able to demonstrate the ability to visualize beads in the terminal location of swine liver
after injection of 0.2mL of packed beads, with increased visualization after additional
0.2mL increments up to 1mL [25]. These quantities are comparable to the amounts we
have imaged. However, in vivo detection is very different than in vitro detection and we
expect to require a much greater amount of beads to provide enough contrast to
visualize microbeads within tumour tissue due to the higher X-ray attenuation of tissue
[26].
An important note about the microbeads we have fabricated is that they are also
expected to be visible in MRI, as superparamagnetic nanoparticles provide high
contrast due to enhanced proton relaxation [27]. It would be useful to image the beads
under MR and compare this to CT results. Depending on the quantity of accumulated
microbeads in tissue vasculature, one of these imaging modalities might prove to be
more useful. Alternatively, the ability to image these microbeads using multiple
imaging modalities may make them desirable candidates for use in investigation of
microbead distribution in tumour sites, or for the visualization of the therapeutic
delivery process.
3.3.4 Cellulose nanocrystal characterization
The proposed multifunctional microbead system outlined in this thesis involves the use
of CNC as a nanocarrier for therapeutic molecules. A necessary step in the use of CNC
for drug conjugation is its functionalization and the quantification of the functionalized
group. Through a hydrolysis reaction using hydrogen peroxide to break down bacterial
cellulose into cellulose nanocrystals, the conversion of the hydroxyl groups to
carboxylic acid groups has been demonstrated [28]. The carboxylic acid group will
serve as the site for drug conjugation through ionic association for a chemotherapeutic
molecule such as Dox. Conditions for and amount of drug conjugation is dependent on
the concentrations of carboxylic acid groups and its pKa. These were determined for
the CNC samples we used by titration.
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The titration curve for CNC (Figure 3.15) illustrates a right-shifted curve relative to the
control sample and the BC sample. The carboxyl content calculated using Equation 2
was found to be 8.36 ± 0.56mmol/g CNC, which is substantially higher than similar
previous work. Spaic reported a carboxyl content of 1.13 ± 0.02mmol/g BC following a
TEMPO-mediated oxidation, and Cook reported a carboxyl content of 0.97 ±
0.18mmol/g CNC using a hydrogen peroxide reaction similar to our work [28]. Other
work, on oxidized cotton derived cellulose, demonstrated an even lower carboxyl
content of 0.7mmol/g [29]. The level of carboxylic group we determined is one of the
highest reported, which is beneficial for Titration
maximum drug loading.
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Figure 3.15 Titration of 0.1g BC and CNC in 1mM HCl with 1mM NaOH.
The pKa of CNC was found to be 3.71, which is comparable to that of other carboxylic
acid groups (formic acid has a pKa of 3.76, and acetic acid has a pKa of 4.74 [30]).
Similar work completed on the oxidation of cellulose report pKa values at 3.90 for BC
[31], and 2.96 for CNC [28]. At appropriate loading conditions, CNC with a pKa in this
range will be able to able to ionically conjugate drug molecules such as as Dox, with a
pKa of 8.3 [32].
We have developed a system that under appropriate conditions, will be able to load
drug molecules such as doxorubicin to the CNC surface. The release mechanism of
drug molecules from the microbead would not only rely on ionic dissociation of the
drug from the CNC, but also diffusion out of the microbead. Based on what has been
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described in section 2.5.1, the diffusion of drug molecules from the PVA matrix can be
controlled through alterations in the processing conditions. For example, if a slow drug
release is desired, additional FTCs can be performed to the microbeads after drug
loading. Release rate and profile from this system can thus be tailored for specific
applications.

3.4 Conclusions
In this chapter, we have demonstrated the ability to produce PVA iron oxide CNC
microbeads through a microfluidic system consisting of a flow-focusing microchannel.
Beads were produced in the desired size range of roughly 100µm equivalent spherical
diameter. The microbead material has been characterized in terms of structure and
morphology, and the presence of iron in the form of iron oxide, specifically magnetite,
has been demonstrated. Microbeads have been shown to have monodisperse iron oxide
nanoparticles embedded, which impart magnetic properties to the material and also
allows for visualization with CT. Microbeads composed of CNC and a high iron oxide
content in PVA are detectable under CT at microbead quantities between 11 and 50mg.
Successful functionalization of CNC with a high carboxyl content has been
demonstrated, showing the potential for drug delivery.
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CHAPTER 4 – ‘Degradable’ PVA Iron Oxide Hydrogel

4.1 Introduction
In this chapter, we explore the use of iron oxide nanoparticle formation in PVA as a
crosslinking method in conjunction with physical crosslinking achieved using low
temperature thermal cycling. Gonzalez et al.’s work on PVA iron oxide gels formed
through low temperature thermal cycling of PVA, followed by the addition of iron ions
and subsequent precipitation into iron oxide demonstrated that the PVA iron oxide gel
had increased degree of crystallinity and melting point [1]. This provides evidence that
iron oxide contributes to crosslinking within the PVA hydrogel. We hypothesized that
the removal of iron from PVA iron oxide hydrogels will reduce the crosslinking, and
therefore stability, of the material, allowing dissolution to occur. Dissolution studies
were performed on bulk hydrogel material and the dissolution was compared for films
in solutions of varying pH and in the presence of iron chelating agents. Iron release and
mass loss data was collected, as well as mechanical testing data. This work
demonstrates the ability of this biomaterial to ‘degrade’ over time, which may be very
advantageous for drug delivery and embolization purposes. The importance of this
work extends to other areas of research involving the use of stimulus-responsive
hydrogels, such as tissue engineering.

4.2 Materials and methods
All chemicals used were ACS reagent grade and purchased from Sigma-Aldrich (St.
Louis, MO, USA). Distilled water was used for all experiments.
4.2.1 Solution preparation
Composition of the solution used was the high iron PVA content (Table 3.1 solution 2)
as listed in chapter 3. The preparation procedure was as detailed in the material and
methods section in chapter 3 (section 3.2.1). A 5wt% PVA solution was used as a
control.
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4.2.2 Hydrogel film fabrication

The solution was poured into moulds (Buna-N rubber) with rectangular openings
(10cm by 5cm by 0.2cm) sandwiched between sheets of Teflon. The Teflon sheets were
held between aluminum sheets and screwed together to ensure the moulds were tightly
sealed. The moulds were placed in a water bath for 6 thermal cycles from 20°C to
-20°C to 20°C at 0.1C/min, with one holding hour at the temperature limits.
Subsequently, films were removed from the moulds and submerged in a 0.5M NaOH
solution for 24 hours. Films were removed and then submerged in water for a day with
constant replacing of the water until the pH reached neutral. Films were then cut into
5mm by 5mm strips and wrapped in plastic wrap and sealed.
4.2.3

X-ray diffraction

Films were dried at 60°C overnight and crushed using mortar and pestle with liquid
nitrogen. XRD was performed using a Rigaku-Rotaflex Diffractometer (RU-200BH)
with a Co-kα radiation (λ =1.79 Å) at 30kV and 44mA. Spectra with a 2θ diffraction
angle were scanned from 0° to 82° with a 0.2° step size. The PVA iron oxide film was
loaded onto a glass slide and the PVA film was loaded onto a glass slide with doublesided tape. A background scan was performed on the blank slide with tape, and the
relative peaks were subtracted from the sample peaks of the applicable sample. Spectra
were plotted from a 2θ of 10° to 82°.
4.2.4

Iron release quantification

Films were removed from the plastic wrap and each sample was weighed. Samples
were placed into 3mL of solutions of water at pH 6, hydrochloric acid (HCl) adjusted to
a pH of 2, or a 0.05M ethylenediametetraacetic acid disodium salt (EDTA) solution, all
at room temperature. After a given amount of time, the sample was removed from
solution and put into new solution. Solutions were analyzed for iron content using
atomic absorption spectroscopy (AAS) (Varian Spectra AA 55) with a multi-element
lamp (Fe/Co/Ni/Mn/Cu/Cr Varian Spectra AA Lamp) at a wavelength of 248.3 nm. The
absorbance was converted into a concentration using a calibration curve of iron
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standard solution (Fluka, Sigma Aldrich) created at the time of each sampling.
Concentration was converted into a mass by multiplying by the volume of the solution.
This was plotted as a fraction of the initial sample mass. This was repeated at various
time points over 101 days and iron release was plotted against time.
4.2.5

Mass loss quantification

At each time point, when the PVA iron oxide film sample was removed from solution,
it was blotted to remove excess liquid, and weighed. The mass loss was plotted against
time. Mass loss was calculated using the following equation.
𝑀𝑎𝑠𝑠  𝑙𝑜𝑠𝑠   % =   

!! !!
!!

×100

(3)

where mi is the initial sample mass and m is the mass of the sample at a given time
point. The first time point of the film mass loss in EDTA solution was excluded
because an increase in mass occurred due to swelling. This is to be expected as a result
of some initial rehydration after the film processing, and was not included in mass loss
data.
4.2.6

Mechanical testing

Tensile testing was completed on film samples to analyze the effect of iron oxide
precipitation in terms of crosslinking the PVA matrix, as well as the removal of iron
oxide. Films both before and after submergence in sodium hydroxide were tested.
Briefly, samples of film were cut into 10mm by 25mm strips. Four different types of
materials were tested: 1) PVA with iron chlorides after 6 FTCs (before iron oxide
precipitation); 2) PVA with iron oxide after 6 FTCs and iron oxide precipitation; 3)
PVA with iron oxide after 6 FTCs and after being treated in EDTA for 2 days; and
finally, 4) PVA with iron oxide after 6 FTCs and after being treated in EDTA for 4
days.
Tensile testing was performed using a hydraulically powered material testing system
(MTS Bionix 858). A 1kg load cell and an attachment for sample loading was used.
The sample thickness was measured using a custom-designed Mitutoyo gauge thickness
tester with samples fit into grooves in aluminum block to prevent deformation.
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Samples were held in a custom-designed tissue grip set with a distance of 20mm
between the two grips. Uniaxial tensile tests were performed at a strain rate of 4mm/s
using a 16mm ramp (constant strain) with a sampling rate of 5kHz. Samples were
subjected to preconditioning prior to testing. This is standard procedure for the purpose
of removing any residual stresses in the material. 10 cycles of preconditioning using a
sine wave with 3.5mm amplitude was used.
Raw data was converted into stress and strain and subsequently plotted. Some negative
stress values resulted and this could be due to several factors. First of all, the samples
used in this work are weak, and because there is noise generated due to the dead weight
of the load cell and sample attachment piece, the data at low strain values may be
partially a result of this noise. This may also be due to the acceleration of the equipment
from 0 to 4mm/s. Some time is required for the machine to respond and accelerate, and
so initial points on the curve may not be accurate. Finally, due to the sample nonuniformity as a result of iron oxide incorporation and release, the stress experienced
does not necessarily follow a predictable trend. For these reasons, negative stress values
were not used in the fitted curves.
Stress-strain data was also converted into elastic modulus at given strain values by
taking the derivative of the stress-strain function. Statistical analysis was performed
using a one-way ANOVA with a Tukey’s post hoc test, and a p-value of <0.05 was
considered significant (GraphPad Prism).

4.3 Results and Discussion
In order to study the dissolution of this material, films were produced rather than
microbeads, as adequate amounts of sample were better able to be produced, and more
reliable measurements could be made. However, the trends seen in this section of the
work are expected to be applicable to the material we have proposed as a
multifunctional visualization and delivery system. One main difference in the
processing of the material was implemented – the number of FTCs was increased to 6
and this was performed before iron oxide precipitation through exposure to a sodium
hydroxide bath. This was due to the challenges in handling the material as some level
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of physical crosslinking is necessary to maintain the dimensional stability of the
hydrogel.
4.3.1 Film characterization
After 6 FTCs, 5% PVA solutions containing iron chlorides resulted in a yellow film
(Figure 4.1A). Following the submergence in a sodium hydroxide bath, the film turned
black in colour (Figure 4.1B).

	
  

Figure 4.1 Films after 6 FTC. A) PVA iron chlorides film (prior to submergence in
NaOH). B) PVA iron oxide film (after submergence in NaOH).
(Note: these films are from separate samples).
XRD of the PVA iron oxide film was performed and compared to a film of plain 5%
PVA (Figure 4.2A). A peak occurring at a 2θ of 22° can be seen in the plain PVA
sample. This is in agreement with other reported data [2,3]. In the PVA iron oxide
sample, the same peak for PVA is displayed, as well as peaks for iron oxide in the form
of magnetite (Fe3O4). Besides the same PVA peak at 22°, six characteristic peaks are
evident, occurring at 35°, 41°, 50°, 63°, 67° and 74°. The peaks and their relative
intensities are consistent with the standard XRD pattern of Fe3O4 shown in Figure 4.2B
(ICCD card 00-019-0629 from PDF-4+ software).
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Figure 4.2 A) XRD pattern of PVA films and PVA iron oxide films. B) ICCD card
for magnetite (number 00-019-0629),
4.3.2 Iron release
The release of iron from the PVA iron oxide hydrogel was studied in release media
containing EDTA (0.05M), HCl (pH 2) and water (pH 6) at room temperature. The
cumulative release of iron over time is displayed in Figure 4.3. It is evident that the
environmental parameters, namely presence of iron chelators and the pH of the solution
surrounding the material, has a significant effect on the rate and quantity of iron
released. A lower pH resulted in a greater release of iron, which is to be expected as a
result of iron oxide solubilization. Furthermore, in the presence of EDTA, a chelating
agent, a much greater amount of iron is released. The low pH (4.43) of the 0.05M
EDTA solution as well as the ability of EDTA to extract and solubilize iron oxide can
explain our observation. In water at pH 6, we see very little release of iron with only a
0.02 ± 0.003wt% release occurring after just over 100 days.
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Figure 4.3 Cumulative iron released from PVA iron oxide films (as a percent of
initial sample mass) over 100 days in solutions of EDTA solution, HCl solution,
and H2O.
To better understand the mechanism of iron release from the material, we investigate
models studied for drug or solute release. A diffusion model for release of drug
molecules or solutes from a thin film has been developed according to Fick’s second
law. Equation 4 is the early time approximation for diffusion-controlled release [4].
!!
!!

!

=4
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  𝑓𝑜𝑟  0
!! !

!

≤ ! ! ≤ 0.6
!

(4)

Mt is amount of solute released at t, M∞ is the total amount of solute loaded, t is time, D
is the diffusion coefficient, and l is the thickness of the matrix.
The system studied in this work was prepared as a film, so the thin film model can be
applied. Since the total amount of solute loaded (M∞) is unknown, this model cannot be
used to its full extent. We are not able to determine D, the diffusion coefficient.
However, Equation 4 can be rearranged to the give Equation 5. It can be seen that the
release amount over time (Mt) is proportional to the square root of time.
!
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(5)

Accordingly, a plot of the cumulative release versus the square root of time was made
for the release in all three media (Figure 4.4). In Figure 4.4, the data correlates linearly
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for the iron release in HCl and H2O solutions with R2 values of 0.997 and 0.955
!

respectively. For the iron release in EDTA, only the initial section (! ! ≤ 0.6) is
!

2

included in the model. Based on this section, a line fits with an R value of 0.991. This
indicates that the cumulative iron release has a linear relationship with the square root
of time when the iron release is less than 60% of the total iron loading. From this, we
can conclude iron release follows the diffusion model, meaning that the release of iron

Percent mass released
in the form or iron (%)

from PVA iron oxide films
is diffusion-controlled.
Sqrt
t graph (modified)
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Figure 4.4 Cumulative iron released from PVA iron oxide films (as a percent of
initial sample mass) versus the square root of time.
4.3.3 Total mass loss/ film dissolution
We hypothesized that the iron oxide nanoparticles provide some level of crosslinking
within the PVA matrix, and the stability of the hydrogel material resulted from a
combination of iron oxide crosslinking and crosslinking from the low temperature
thermal cycling process. As iron is removed from the sample, the material will begin to
fall apart. However, we are unable to determine if degradation, or rather erosion – a
physical dissolution and diffusion of a polymer [5], of the material has occurred simply
from the iron release results. Release from a degradable matrix can occur through one
of three methods: release from physical entrapment as the polymer degrades, release as
covalent bonds between the drug and polymer are broken, or diffusion controlled
release from physical entrapment followed by delayed polymer degradation [6].
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Because we have demonstrated the iron release follows a diffusion-controlled release
mechanism, the most likely method of degradation, if it does indeed occur, is the third
alternative.
The amount of total hydrogel mass lost in solution over time was measured and
compared to plain PVA films containing no iron oxide as control (Figure 4.5). Samples
placed in EDTA and HCl solutions were plotted. Both the PVA iron oxide film and
plain PVA film samples submerged in water actually increased in mass, due to swelling
as the sample rehydrated and reached equilibrium. Because of this, and the low release
of iron, the samples in water are not shown. Data for the samples in water can be seen
in Appendix V.
As shown in Figure 4.5, the rate of dissolution of the PVA iron oxide material is much
greater than that of the control PVA samples. In fact, at 45 days, the total mass loss of
PVA iron oxide films is 4.45 and 3.59 times greater than plain PVA films in HCl and
EDTA respectively. Similarly, at 73 days, the total mass loss of PVA iron oxide films is
4.08 and 3.41 times greater than PVA films in HCl and EDTA respectively (raw data in
Appendix V). The amount of film mass loss over time could be a result of any, or a
combination of, the three following effects: iron extraction, osmotic effect, or PVA
dissolution.Film Dissolution in EDTA
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Figure 4.5 Total mass lost from PVA iron oxide films and PVA films (as a percent
of initial sample mass) over 100 days in A) EDTA solution B) HCl solution.
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First of all, we have demonstrated that the release of iron occurs in the PVA iron oxide
films. This contributes to a mass loss of approximately 2.94wt% and 0.45wt% of the
initial sample mass in EDTA and HCl respectively. Secondly, in the presence of salts,
we expect an osmotic effect to occur and water to be driven out the hydrogel. Results
reported by Patachia et al. demonstrated an approximate 10% mass loss of PVA
hydrogels in 1M salt solutions, and this reached equilibrium after roughly 25 hours. In
3M salt solution, mass loss increased to roughly 40% [7]. This phenomenon likely
contributes to some of the mass loss, especially in the initial time points as it reaches
equilibrium. However, the concentration of ethylenediametetraacetic acid disodium salt
(EDTA) used in our work was 0.05M, much lower than electrolyte concentrations used
in work by Patachia et al., and therefore mass loss due water loss through an osmotic
effect is expected to be significantly lower. As well, the difference in mass loss shown
for PVA iron oxide films relative to control PVA films support the claim that water loss
through osmotic effect is not the only other contributing factor. PVA dissolution must
account for the remaining mass loss.
Small amounts of PVA dissolution typically occur in PVA hydrogels produced through
the LTTC process from the amorphous regions of the hydrogel [8-11]. In our
experiment, there is likely to be some dissolution of PVA in both PVA iron oxide films
and control PVA films. However, the difference in mass loss for the PVA iron oxide
films and control PVA films is significant. The difference between these two samples is
the presence of iron oxide, but the difference in mass loss cannot be attributed to solely
through loss of iron or loss of water. This indicates that the presence, and subsequent
removal, of iron oxide from the film actually affects the degree of PVA dissolution,
resulting in much greater PVA dissolution.
4.3.4 Contribution of iron release to film dissolution
An additional comparison can be made by comparing the shape of the curves for iron
release and total mass loss (Figure 4.6). When cumulative iron released and total mass
lost are plotted together, very similar curves are observed over time. This occurs for
films in both the EDTA and HCl solutions. The rates of iron release and total mass loss
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are very similar, which clearly demonstrates the effect that iron release has on the
dissolution of the entire hydrogel material.
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Figure 4.6 Total mass lost and cumulative iron released (both as a percent of
initial sample mass) over 100 days in A) EDTA solution, and B) HCl solution. The
left hand y-axis displays total mass lost (%) and the right hand y-axis displays
cumulative iron released (%).
The total mass loss of PVA iron oxide films after over 100 days in EDTA and HCl are
53.6 ± 5.2%, 41.6 ± 2.9% (Figures 4.5 and 4.6). This is a substantial amount of
dissolution, as roughly half of the original sample mass has disappeared. PVA iron
oxide film results in a greater extent of dissolution compared to plain PVA film in the
presence of low pH and chelating agents. It is difficult to make direct comparisons with
work in the literature as samples were prepared using PVA of different molecular
weights, solution concentrations, and types of dissolution media [7,9-11]. However,
there do not seem to be any reports of PVA hydrogels reaching the extent of dissolution
that we have found in this work on PVA containing iron oxide.
4.3.5 Mechanical testing
To confirm that iron oxide takes part in the crosslinking of the hydrogel matrix, and
also that the release of iron aids in the material dissolution, mechanical testing was
performed on the samples. Figure 4.7 shows stress-strain curves for four different
materials: 1) PVA with iron chlorides after 6 FTCs (before iron oxide precipitation); 2)
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PVA with iron oxide after 6 FTCs and iron oxide precipitation; 3) PVA with iron oxide
after 6 FTCs and after being treated in EDTA for 2 days; and finally, 4) PVA with iron
oxide fully after 6 FTCs and after being treated in EDTA for 4 days. Treatment in
EDTA was completed because this solution had the most accelerated iron extraction, so
would be able to accomplish iron release quickly and demonstrate the effect of iron
release on material strength. PVA iron chlorides films (1) was crosslinked only through
the low temperature thermal cycling process; PVA iron oxide films (2) was crosslinked
through both the LTTC process as well as iron oxide precipitation; and the PVA iron
oxide films after treatment in EDTA (3 and 4) were crosslinked through the LTTC
process and iron oxide precipitation, and subsequently had iron released into solution
for various amounts of time.
A	
  

B	
  

C

D	
  

A	
  

Figure 4.7 Stress-strain curves for four film samples. A) PVA iron chlorides film.
B) PVA iron oxide film. C) PVA iron oxide film after EDTA treatment for 2 days.
D) PVA iron oxide film after EDTA treatment for 4 days.
Stress-strain data for PVA based materials is non-linear, and several equations have
been proposed to model this data [12]. After attempting several different models, a
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commonly used exponential model with two fitting parameters (Equation 6) was found
to be the best fit for the data present here.
𝜎 = 𝐴𝑒𝑥𝑝(𝐵𝜀)

(6)

The material that was treated in EDTA for 4 days became so weak that three of the
samples broke during testing. The two sets of sample data plotted in Figure 4.7D are
extremely noisy and random. The material became so weak that it passed the limit that
our equipment is accurately able to test. For these reasons, this data was not included in
the following comparison.
Figure 4.8 shows the fitted curves for materials shown in Figures 4.7 A, B, and C. The
PVA iron chlorides stress-strain curve is the lowest on the graph, meaning it is the
weakest material (curve A). After iron oxide precipitation, the stress strain curve
increases, indicating that there is a strengthening of the material after the iron chlorides
are converted into iron oxide (curve B). This supports the notion that the precipitation
of iron oxide within the PVA matrix provides a certain level of crosslinking. The film
treated in EDTA for two days has a lower curve in between curves A and B, indicating
weakening in the material after iron was released but it was still stronger than the
sample with no iron oxide crosslinking (curve C). This confirms that iron removal
weakens the material, and is consistent with the dissolution of the material.
Mech testing data comparison

Stress (MPa)

0.015

B
PVA iron chlorides
PVA iron oxide
PVA iron oxide
treated (2 days)

C
A

0.010

0.005

0.000
0.0

0.2

0.4

0.6

0.8

Strain

Figure 4.8 Fitted stress-strain curves for PVA iron chloride film, PVA iron oxide
film, and PVA iron oxide film after EDTA treatment for 2 days.
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A comparison of the elastic modulus of the three materials at a strain of 50% shows a
similar trend (Figure 4.9) and there is a significant difference between the elastic
modulus of the PVA iron oxide films compared to the PVA iron oxide films after 2
days of treatment in EDTA solution. This indicates that the release of iron into EDTA
solution weakens the material significantly, providing further evidence that material
dissolution occurs due to the reduction in crosslinking. It is important to note that the
EDTA solution used does not represent tissue conditions, and we chose to treat the
films in this solution mainly to accelerate the iron release for demonstration of material
dissolution.

Elastic Modulus at 50% Strain
Elastic Modulus (MPa)

0.04
0.03

PVA iron chlorides
PVA iron oxide

0.02

PVA iron oxide
treated (2 days)

0.01
0.00

Figure 4.9 Elastic modulus at 50% strain for PVA iron chloride film, PVA iron
oxide film, and PVA iron oxide film after EDTA treatment for 2 days.
In this work, 6 FTCs were used to stabilize the film prior to iron oxide precipitation.
This is the maximum number of FTCs shown to cause a difference in plain PVA
hydrogel crosslinking extent [13,14], although this may be different in PVA containing
iron chlorides. We expect that if fewer FTCs were performed on this material,
weakening with iron oxide removal would occur at a faster rate. This provides an
approach to tune the rate of dissolution of the PVA hydrogels for specific applications.
When we relate the material studied in this section to the microbeads produced in
chapter 3, there are a few notable differences. First of all, the geometry is different.
Diffusion from a sphere is different from a thin film, so we expect that the rate of iron
release, and subsequent material dissolution, would be different. Secondly, precipitation
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of iron oxide occurs before low temperature thermal cycling for the microbeads. This
provides enough bead stability that 6 FTCs are not required. If only one FTC is used on
the beads after iron oxide precipitation, for example, we expect that the dissolution of a
bead may occur much quicker, or to a fuller extent, than the film described here. This is
promising for application as a ‘degradable’ multifunctional drug delivery system.
The media that we have performed dissolution in does not perfectly resemble that of
physiological tissue. However, we have been able to determine the trends that affect the
dissolution of this material. A low pH enhances iron release and material dissolution, as
does the presence of chelating agents to extract iron. Tumour tissue has a pH that is
slightly lower than that of healthy tissue, sitting at roughly at 6.5 [15]. There are also
many natural chelating agents present in the body. Specifically, transferrin, mainly
produced in the liver, is a binding protein in the blood that facilitates iron uptake [16].
These types of environmental conditions present in the body may assist in the
dissolution of PVA iron oxide material.

4.4 Conclusions
In this chapter, we have produced films using a combination of low temperature
thermal cycling and iron oxide precipitation and studied the effect of the two forms of
crosslinking together. We were able to demonstrate that iron is released by a diffusioncontrolled process from PVA Fe3O4 films over time, and this is highly dependent on
environmental parameters. A lower pH and presence of chelating agents result in
enhanced iron release. Additionally, we have shown that the release of iron from the
film corresponds to a total mass loss of the material, and this total mass loss happens to
a much greater extent for PVA Fe3O4 films compared to plain PVA films. Mechanical
testing demonstrated that iron oxide precipitation does strengthen the material, and then
subsequent iron release weakens it, resulting in eventual breakage. Overall, we have
shown that this PVA iron oxide hydrogel material can ‘degrade’ over time by a
dissolution mechanism in the presence of low pH or through the extraction of iron,
which has not been shown for physically crosslinked PVA hydrogels otherwise. This
ability to degrade is important for the application of multifunctional visualization and
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drug delivery systems as they will degrade rather than accumulate in the body. Material
with properties such as this could also find application in other areas, such as tissue
engineering, as a dissolvable, magnetically stimulated scaffold material.
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CHAPTER 5 – Conclusions and Future Goals
There is a constant need to improve treatment of cancer as it remains a highly prevalent
and deadly illness. For loco-regional treatment of liver cancer tumours, the use of drugeluting embolization microbeads is a very promising treatment. However, areas of
improvement have been identified, and work to enhance the products used for this
treatment could translate into a better understanding of the treatment as well as
improved patient outcomes. We have identified several main design criteria for a novel
multifunctional ‘nano-on-micro’ visualization and delivery system that incorporates
improvements to current systems, and we attempted to address these through the work
presented in this thesis.
We have demonstrated the production of PVA iron oxide CNC microbeads that can be
visualized with CT, have magnetic properties which could allow magnetic localization,
have the potential to be loaded with therapeutics, and are composed of a material that
we have shown to ‘degrade’ over time. This multifunctional system has many desirable
properties that make it a good candidate for use in TACE or other contrast enhancement
and drug delivery applications.
There are several directions that this work can follow moving into the future. We would
like to see these microbeads visualized with MRI, as the presence of magnetite
nanoparticles lends itself well to this type of imaging. As well, we would like to
explore, in detail, the drug loading and release mechanisms of this system with
doxorubicin. It would also be interesting and valuable to explore the magnetic
localization capability of these microbeads. Additionally, the dissolution study
performed on the bulk hydrogel material should be compared to dissolution of the
microbeads themselves. Finally, in terms of application, researching the use of these
microbeads in animal models would be a logical step to determine their viability as a
visible drug-eluting embolization system.
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Indeed, the work that we have completed here demonstrates the production of a
promising system that should be further studied for use as a multifunctional
visualization and drug delivery system.
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APPENDICES
Appendix I – Bacterial Cellulose Growth and Harvest Procedure
The bacterial cellulose (BC) was grown in a static culture with media consisting of
0.22M fructose, 26.63mM ammonium sulphate, 7.34mM monobasic potassium
phosphate, 1.01mM magnesium sulphate heptahydrate, 14.28mM tri-sodium citrate,
45.80mM citric acid and 5g/L yeast extract. 200mL of media were placed in 500mL
Erlenmeyer flasks, autoclaved for 30 minutes, inoculated with G. xylinus (BPR 2001)
bacteria that was cultivated in our lab, and sealed with glass wool and tinfoil. The flasks
were stored in an incubator at room temperature for 3 weeks before extracting the
cellulose. The cellulose pellicles that formed were removed from the flasks and blended
with water using a Commercial Laboratory Blender (51BL30). The mixture was
centrifuged at room temperature at 15,000 rpm for 5 minutes (Sorvall Refrigerated
Superspeed Centrifuge; model RC-5B & RC-5C), and the collected sample was resuspended in a 1w/v% NaOH solution for 3 hours at 80°C to remove any remaining
bacterial cells. The mixture was again centrifuged, collected and re-suspended in water
and this was repeated three times for adequate washing. The resulting cellulose was
stored at 4°C.
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Appendix II – Standard XRD Pattern for Magnetite
Corresponding to ICCD card number 00-019-0629
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A to mic p ara m eters are cro s s-refere n c e d fro m P D F e ntry 04-008-8145
C ry stal (S y m m etry A llo w e d): C entrosymmetric
SG Symmetry Operators:
Seq Operator
Seq
1
x,y,z
11
2
-x,-y,-z
12
3
x,-y+1/4,-z+1/4
13
4
-x,y+3/4,z+3/4
14
5
-x+1/4,y,-z+1/4
15
6
x+3/4,-y,z+3/4
16
7
-x+1/4,-y+1/4,z
17
8
x+3/4,y+3/4,-z
18
9
z,x,y
19
10
-z,-x,-y
20
Atomic Coordinates:
Atom Num Wyckoff
Fe
1
8a
Fe
2
16d
O
3
32e

Operator
z,-x+1/4,-y+1/4
-z,x+3/4,y+3/4
-z+1/4,x,-y+1/4
z+3/4,-x,y+3/4
-z+1/4,-x+1/4,y
z+3/4,x+3/4,-y
y,z,x
-y,-z,-x
y,-z+1/4,-x+1/4
-y,z+3/4,x+3/4

Symmetry
-43m
.-3m
.3m

x
0.125
0.5
0.255

Anisotropic Displacement Parameters:
Atom Num Bani11
Bani22
Bani33
Fe
1
0.617656 0.617656 0.617656
Fe
2
0.701882 0.701882 0.701882
O
3
0.729958 0.729958 0.729958

Seq
21
22
23
24
25
26
27
28
29
30
y
0.125
0.5
0.255

Operator
-y+1/4,z,-x+1/4
y+3/4,-z,x+3/4
-y+1/4,-z+1/4,x
y+3/4,z+3/4,-x
x,z,y
-x,-z,-y
x,-z+1/4,-y+1/4
-x,z+3/4,y+3/4
-x+1/4,z,-y+1/4
x+3/4,-z,y+3/4
z
0.125
0.5
0.255

Bani12
0.0
0.0280753
0.0280753

SOF
1.0
1.0
1.0

Seq
31
32
33
34
35
36
37
38
39
40

Biso
0.61765
0.70188
0.72995

Bani13
0.0
0.0280753
0.0280753

Operator
-x+1/4,-z+1/4,y
x+3/4,z+3/4,-y
y,x,z
-y,-x,-z
y,-x+1/4,-z+1/4
-y,x+3/4,z+3/4
-y+1/4,x,-z+1/4
y+3/4,-x,z+3/4
-y+1/4,-x+1/4,z
y+3/4,x+3/4,-z

Seq
41
42
43
44
45
46
47
48

O rigin: O 2

Operator
z,y,x
-z,-y,-x
z,-y+1/4,-x+1/4
-z,y+3/4,x+3/4
-z+1/4,y,-x+1/4
z+3/4,-y,x+3/4
-z+1/4,-y+1/4,x
z+3/4,y+3/4,-x

AET
4-a
6-a
4-a

Bani23
0.0
0.0280753
0.0280753

C ommon Phase, E ducational P attern, F orensic, Inorganic, Metals & Alloys, Micro & Mesoporous, Mineral R elated
S u bfile(s): (Mineral , Synthetic), N B S P attern, Pigment/Dye
Prototy p e Stru cture: Mg Al2 O 4
Prototy p e Stru cture [A lp h a O rd er]: Al2 Mg O 4
Min eral C la s sific atio n: Spinel (Supergroup), 1 C-oxide (Group)
P e ars o n: c F 56.00
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00-019-0629

00-011-0614
01-075-0449
04-001-7909
04-002-0618
04-002-2707
04-002-3668
04-002-5683
04-002-8141
04-003-1446
04-005-4551
04-005-9788
C ro s s-R ef P D F #'s: 04-006-1668
04-006-6497
04-007-1427
04-007-8976
04-008-4423
04-009-4225
04-009-8420
04-009-8424
04-009-8428
04-009-8435
04-009-8439
E ntry D ate: 09/01/1969

Apr 16, 2015 2:07 PM (O wner)

(D eleted), 00-026-1136 (Primary), 01-072-2303 (Alternate), 01-074-1909 (Alternate),
(Alternate), 01-075-1610 (Alternate), 01-076-1849 (Alternate), 04-001-7822 (Alternate),
(Alternate), 04-001-9000 (Alternate), 04-001-9326 (Alternate), 04-002-0264 (Alternate),
(Alternate), 04-002-0643 (Alternate), 04-002-1855 (Alternate), 04-002-2487 (Alternate),
(Alternate), 04-002-2709 (Alternate), 04-002-2981 (Alternate), 04-002-3194 (Alternate),
(Alternate), 04-002-5310 (Alternate), 04-002-5448 (Alternate), 04-002-5632 (Alternate),
(Alternate), 04-002-5903 (Alternate), 04-002-6866 (Alternate), 04-002-6955 (Alternate),
(Alternate), 04-002-8629 (Alternate), 04-002-9019 (Alternate), 04-002-9635 (Alternate),
(Alternate), 04-004-2838 (Alternate), 04-005-4307 (Alternate), 04-005-4319 (Primary),
(Alternate), 04-005-5733 (Alternate), 04-005-6268 (Alternate), 04-005-9786 (Alternate),
(Alternate), 04-005-9815 (Alternate), 04-006-0225 (Alternate), 04-006-0425 (Alternate),
(Alternate), 04-006-2406 (Alternate), 04-006-2467 (Alternate), 04-006-2752 (Alternate),
(Alternate), 04-006-6550 (Alternate), 04-006-6692 (Alternate), 04-006-8076 (Alternate),
(Alternate), 04-007-2718 (Alternate), 04-007-6010 (Alternate), 04-007-8567 (Alternate),
(Alternate), 04-007-9093 (Alternate), 04-008-0315 (Alternate), 04-008-0777 (Alternate),
(Alternate), 04-008-4511 (Alternate), 04-008-4512 (Alternate), 04-008-8145 (Alternate),
(Alternate), 04-009-8417 (Alternate), 04-009-8418 (Alternate), 04-009-8419 (Alternate),
(Alternate), 04-009-8421 (Alternate), 04-009-8422 (Alternate), 04-009-8423 (Alternate),
(Alternate), 04-009-8425 (Alternate), 04-009-8426 (Alternate), 04-009-8427 (Alternate),
(Alternate), 04-009-8429 (Alternate), 04-009-8430 (Alternate), 04-009-8431 (Alternate),
(Alternate), 04-009-8436 (Alternate), 04-009-8437 (Alternate), 04-009-8438 (Alternate),
(Alternate), 04-009-8440 (Alternate), 04-011-5952 (Alternate)

References:
Type
Primary R eference
Crystal Structure
O ptical D ata

DOI

Reference
N atl. Bur. Stand. (U. S. ) Monogr. 25 5, 31 (1967).
Crystal Structure Source: LP F .
D ana's System of Mineralogy, 7th E d. I, 698.

Additional P atterns: To replace 00-011-0614. S e e 00-026-1136. S e e 20596 (P D F 01-072-2303); 27898
(P D F 01-074-1909); 29129 (P D F 01-075-0449); 31157 (P D F 01-075-1610); 36314 (P D F 01-076-1849);
30860 (P D F 01-075-1372); 65338 (P D F 01-079-0416); 65339 (P D F 01-079-0417); 65340 (P D F
01-079-0418); 65341 (P D F 01-079-0419); 68181 (P D F 01-080-0389); 68182 (P D F 01-080-0390) and
75627 (P D F 01-082-1533). Analysis: Spectrographic analysis showed the following major impurities: 0.01 to
D ata b a s e C o m m e nts: 0.1% C o, 0.001 to 0.01% Ag, Al, Mg, Mn, Mo, Ni, Si, Ti and Zn. C olor: Black. G eneral C omments: O ther
data 00-025-1376. O paque O ptical D ata: O paque mineral optical data on specimen from Bra astad, Norway:
R R2R e=20.1, Disp.=16, V H N100=592, C olor values=.311, .314,. S ample Source or Locality: S ample
obtained from the C olumbian C arbon C o., N ew York, N Y, U S A. T emperature of D ata C ollection: P attern
taken at 298 K. Unit C ell: a=8.3967 refined in 1975. Unit C ell D ata Source: Powder Diffraction.
d-Spacings (21) - 00-019-0629 (Fixed Slit Intensity) - Co K1 1.78896 Å
2 (°)
d (Å)
I
h k l *
2 (°)
d (Å)
I
h
21.2468
4.852000 8
1 1 1
74.1050
4
1.484500 40
35.0926
2 2 0
78.1402
1.419200 2
5
2.967000 30
41.3749
84.7076
1.327700 4
6
2.532000 100 3 1 1
43.3035
2.424300 8
2 2 2
88.6024
1.280700 10
5
50.4387
2.099300 20
4 0 0
89.9173
1.265900 4
6
62.8906
1.714600 10
4 2 2
95.1364
1.211900 2
4
67.2264
1.615800 30
5 1 1
105.7173 1.122100 4
6

k
4
3
2
3
2
4
4

l
0
1
0
3
2
4
2

*
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2 (°)
109.8442
116.9058
129.3458
134.6243
136.4521
144.6488
175.4038

d (Å)
1.093000
1.049600
0.989600
0.969500
0.963200
0.938800
0.895200

I
12
6
2
6
4
4
2

h
7
8
6
7
6
8
6

k
3
0
6
5
6
4
6

l
1
0
0
1
2
0
4

*
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Appendix III – Alternative Microfluidic Device Designs
Three designs that tested for microbead production are shown in Table 1.
Table 1. Microchannel device designs for production of PVA iron oxide CNC
microbeads

	
  

	
  

	
  

	
  
	
  

	
  

	
  
	
  	
  
	
  	
  
	
  
	
  	
  

Dispersed phase (PVA
iron phase) flows
perpendicular to the
continuous phase (oil
phase), meeting at a
T-junction.

Dispersed
phase

	
  

	
  

Red channel width is
127µm. Blue channel
width is 500µm.
Description

Continuous phase

	
  

	
  

	
   	
  

3. Flow-focusing
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phase

	
  

Continuous phase

	
  	
  	
  
	
  
	
  	
  	
  
	
  

2. Modified T-junction

	
  

Figure

1. T-junction

	
  

Design

	
  

Red channel width is
127µm. Blue channel
width is 500µm.
Dispersed phase (PVA
iron phase) flows
perpendicular to the
continuous phase (oil
phase), meeting at a Tjunction with a raised
notch to improve
shearing of the
microbead from the wall.

	
  	
  
	
  
	
  
	
  	
  
Red channel width is
200µm with a narrow
section of 127µm.
Blue channels have a
width of 500µm.
Dispersed phase (PVA
iron phase) flow is
directed through a
channel by the
continuous phase (oil
phase) flowing from
two directions.

The initial T-junction design resulted in the formation of slugs – elongated droplets – of
the dispersed phase. Quite rapidly, this transformed into a stream of the dispersed phase
flowing along the side of the microchannel, parallel to the oil phase. Beads could not
be produced this way, but instead a constant stream of the dispersed phase solution
resulted. The modified T-junction design allowed for production of microbeads.
Images of the dispersed phase flowing against a continuous phase in the modified Tjunction design are shown in Figure 1 and 2. Initially, fully formed beads were
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produced (Figure 1), followed quickly by bead slugging (Figure 2). An additional issue
associated with the use of this design was the size limit that existed. The large channel
was 500µm in width, and even with a change in the flow rates, beads filled the entire
channel (Figure 3.4). This was not able to produce beads of the desired particle size.
The flow-focusing design was successful for microbead production.

Figure 1. Microbead production using modified T-junction microchannel. The red
arrow indicates the PVA iron phase flow and the blue arrow indicates the oil
phase flow.

Figure 2. Microbead slugging in modified T-junction microchannel. The red arrow
indicates the PVA iron phase flow and the blue arrow indicates the oil phase flow.
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Appendix IV – Iron oxide nanoparticle size measurement
A

B

C

D

E

F

Figure 1. A,C,E) TEM images of iron oxide nanoparticles in PVA matrix. B,D,F)
Corresponding outlines of particles analyzed by Image J particle analyzer with
threshold set between 0-80.
	
  

	
  
	
  

93

Figure 2. Histogram of equivalent spherical diameter of iron oxide nanoparticles
in PVA matrix from TEM images.
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Appendix V – Data for Iron Release and Mass Loss From PVA Iron Oxide
Films
Table 1. Cumulative iron released from PVA iron oxide films as a percent of
initial sample mass in EDTA solution
Time (days)
0
2.05
4.07
6.02
8.94
15.01
25.06
35.12
45.06
55.06
73.07
100.99

Average Fe release (%)
0
0.637
1.081
1.287
1.527
1.889
2.289
2.619
2.856
2.920
2.930
2.941

Standard deviation (%)
0
0.040
0.067
0.114
0.116
0.143
0.127
0.148
0.131
0.132
0.134
0.144

Table 2. Cumulative iron released from PVA iron oxide films as a percent of
initial sample mass into HCl solution
Time (days)
0
3
4.00
6.00
9
15.07
25.16
35.06
45.07
54.91
73.09
102.03

Average Fe release (%)
0
0.074
0.093
0.124
0.153
0.192
0.239
0.276
0.313
0.346
0.391
0.451

Standard deviation (%)
0
0.006
0.006
0.009
0.010
0.012
0.013
0.014
0.016
0.018
0.020
0.024

Table 3. Cumulative iron released from PVA iron oxide films as a percent of
initial sample mass into H2O
Time (days)
0
25.13
73.05
101.98
	
  

Average Fe release (%)
0
0.008
0.014
0.020

Standard deviation (%)
0
0.001
0.002
0.003
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Table 4. Mass lost of PVA iron oxide films in EDTA solution as percent of initial
sample mass
Time
(days)
0
2.05
4.07
6.02
8.94
15.01
25.06
35.12
45.06
55.06
73.07
100.99

PVA Iron Oxide
Average
percent loss
(%)
0
-10.442
2.388
9.549
16.115
26.593
34.043
39.165
44.168
47.573
50.083
53.609

Standard
deviation
(%)
0
3.823
2.043
3.126
3.400
3.182
3.332
3.913
3.433
3.113
3.755
5.151

Time
(days)
0
2.001
4.088
6.066
8.007
15.128
26.212
37.139
45.219
55.059
73.080

PVA
Average
percent loss
(%)
0
1.943
3.857
5.203
5.123
12.329
11.328
12.220
12.266
13.840
14.738

Standard
deviation
(%)
0
1.932
2.206
2.586
3.209
3.966
2.417
1.764
3.086
1.992
1.879

Table 5. Mass lost of PVA iron oxide films in HCl solution as percent of initial
sample mass
Time
(days)
0.00
3.00
4.00
6.00
9.00
15.07
25.16
35.06
45.07
54.91
73.09
102.03

	
  

PVA Iron Oxide
Average
Standard
percent loss
deviation
(%)
(%)
0.000
0.000
8.137
2.989
9.266
3.088
10.142
3.252
13.069
6.604
15.394
3.508
19.305
3.950
22.874
4.420
26.660
3.836
30.069
3.396
33.866
3.579
41.553
2.944

Time
(days)
0.000
2.005
4.090
6.066
8.009
15.132
26.212
37.139
45.219
55.063
73.083

PVA
Average
percent loss
(%)
0.000
1.054
0.230
2.084
0.937
6.100
4.616
7.543
5.957
6.607
8.278

Standard
deviation
(%)
0.000
3.204
3.410
3.452
4.085
5.695
3.896
4.931
4.614
5.815
4.160
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Table 6. Mass lost of PVA iron oxide films in H2O solution as percent of initial
sample mass
Time
(days)
0.00
25.13
73.05
101.98

	
  

PVA Iron Oxide
Average
percent loss
(%)
0.000
-39.168
-45.040
-31.708

Standard
deviation
(%)
0.000
4.181
2.882
6.828

Time
(days)
0.000
26.214
73.083

PVA
Average
percent loss
(%)
0.000
-9.508
-3.849

Standard
deviation
(%)
0.000
4.540
3.977
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